Isolation and Characterisation of Relaxed Specificity I-TevI Nuclease Domain Mutants by Roy, Alexander C
Western University 
Scholarship@Western 
Electronic Thesis and Dissertation Repository 
9-18-2015 12:00 AM 
Isolation and Characterisation of Relaxed Specificity I-TevI 
Nuclease Domain Mutants 
Alexander C. Roy 
The University of Western Ontario 
Supervisor 
Prof. David R. Edgell 
The University of Western Ontario 
Graduate Program in Biochemistry 
A thesis submitted in partial fulfillment of the requirements for the degree in Master of Science 
© Alexander C. Roy 2015 
Follow this and additional works at: https://ir.lib.uwo.ca/etd 
 Part of the Biochemistry Commons 
Recommended Citation 
Roy, Alexander C., "Isolation and Characterisation of Relaxed Specificity I-TevI Nuclease Domain Mutants" 
(2015). Electronic Thesis and Dissertation Repository. 3258. 
https://ir.lib.uwo.ca/etd/3258 
This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted 
for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of 
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca. 
ISOLATION AND CHARACTERISATION OF RELAXED SPECIFICITY 
I-TevI NUCLEASE DOMAIN MUTANTS
by
Alexander C.  Roy
Submitted in partial fulfillment of the requirements
for the degree of Master of Science
at
Western University
London, Ontario
August 2013
 © Copyright by Alexander C.  Roy, 2015
i
ABSTRACT
Engineering nucleases is important to the advancement of genetic engineering
and gene therapy approaches. Engineering requires a knowledge of which residues
are contributing to each function of the nuclease. The residues which contribute to
cleavage specificity of the I-TevI nuclease domain (ND) are unknown. I suspect that
some of  these contributions derive from the ND, thus my null  hypothesis  is  that
mutation  of  the  ND  will  not  alter the  substrates  this  enzyme  can  cut.  I  have
mutagenised the I-TevI nuclease domain and using directed evolution I have isolated
mutations  which  were  characterised  in  vivo and  in  vitro.  These  mutations  permit
cleavage  of  otherwise  cleavage  resistant  substrates,  indicating  that  the  ND  does
contribute to cleavage specificity. Mutations which provided the greatest increase in
activity  against  cleavage  resistant  substrates  (K26R,  T95S,  and  Q158R)  were
combined into a single relaxed specificity nuclease domain which exhibits 1.2-5-fold
improved cleavage of resistant substrates.
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1Chapter 1 INTRODUCTION
Engineering nucleases is important for the advancement of genome editing,  a
core component  of  genetic  engineering and gene therapy approaches1-3. Optimally,  a
system would be developed such that a nuclease could be immediately identified and
produced  to  edit  any  gene.  Such  an  enzyme  would  have  to  specifically  target  an
extended DNA sequence to ensure editing at a single unique site in a genomic context.
This level of specificity requires extensive protein-DNA contacts over a long stretch of
DNA.  Homing  endonucleases  (HEs)  are  a  class  of  nucleases  that  recognise  DNA
sequences that are 12-40 bp in length, a characteristic that allows them to potentially
effect a genetic change at a single position in a host organism's genome4. HEs effect
contacts over these lengthy DNA sequences through the combination of multiple DNA
binding 'modules' that each contribute to the relative degree of cleavage that a nuclease
can effect on each of a related set of substrates, hereafter called its cleavage profile.
These modules can be recombined to generate libraries of engineered nucleases, each
with  a  unique  cleavage  profile.  Such libraries  could  represent  a  source  of  versatile
genome editing tools.
I-TevI  is  a  HE comprised of  three  modules:  an N-Terminal  nuclease domain
(ND), a C-terminal DNA binding domain (DBD), and a linker region that connects the
two  domains5.  The  I-TevI  ND  has  been  recombined  with  other  DBDs  to  generate
chimaeric nucleases that combine the cleavage profile of the chosen DBD with that of
the I-TevI ND6. The range of cleavage profiles possible from chimaeric nucleases like
these could be further extended by rationally designing a library of engineered I-TevI
NDs with  distinct  cleavage profiles.  Rational  design  of  a  nuclease  requires  that  the
2amino acids which contribute to DNA sequence readout are known; this is not the case
for the I-TevI ND.
 In this thesis I describe how I used directed evolution to screen for mutant I-
TevI NDs that were able to cleave otherwise poorly cleaved DNA substrates. Further, I
describe the process by which I isolated and characterised the impact of mutations that
were identified from the screens on the I-TevI ND cleavage profile in vivo and in vitro.
Subsequently,  I  relate  the  identified  mutations  and  their  impacts  on  the  I-TevI  ND
cleavage  profile  to  previously  identified  mutations  in  the  I-TevI  ND  and  to  other
attempts to develop nucleases with altered cleavage profiles. Finally, I give an insight
into how these mutant NDs will be used to better understand the source of its cleavage
profile towards the ultimate goal of rationally designing a library of I-TevI NDs with
unique cleavage profiles for use in genome editing.
1.1 Genome Editing
Genome editing is a technique in which a specific genetic locus of an organism's
genome is targeted for removal, replacement, or insertion of new genetic material. The
editing process is facilitated by nucleases that recognise the chosen target locus, and
create a nick or double-strand break (DSB) within the locus. The breakage of a DNA
strand  then  elicits  the  DNA  repair  pathways  to  mend  the  break,  either  by
nonhomologous end joining (NHEJ), microhomology-mediated end joining (MMEJ), or
homology-directed repair (HDR), which can be utilised to effect genetic changes. The
variety and versatility of genome editing tools has seen a tremendous amount of growth
in the past decade. These genome editing tools are typically exploited by one of two
3related fields: genetic engineering (§ 1.1.2) or gene therapy (§ 1.1.3).
1.1.1 Mechanisms of Genome Editing with Nucleases
Genome editing with nucleases is achieved by eliciting DNA repair pathways,
each of which offer unique opportunities for editing (Figure 1.1)7. NHEJ, and MMEJ
can remove nucleotides surrounding the site of damage and thus can be used to create a
deletion or gene knock-out; HDR uses a template to effect reconstruction of the broken
strand, and thus if a donor template is provided, the owriginal sequence surrounding the
break can be replaced with a DNA sequence from the donor template.
1.1.2 Genome Editing in Genetic Engineering 
Genetic engineering is the artificial genetic modification of an organism in order
to make it more useful in a particular context. Genetic engineering is used extensively in
the field of biomedical research to create genetically modified organisms that provide
model systems for human diseases8. Other genetically modified organisms created using
genetic engineering include knock-out and knock-in mice, which express an aberrant
phenotype that facilitates an understanding of gene function9. Genetic engineering can
also  be  used  to  create  gene-fusions  that  encode  a  protein  of  interest  joined  with  a
reporting  element  such  as  green  fluorescent  protein  which  allow  for  tracking  and
localisation of said protein in a single-cell or whole-organism context10,11.
Genetic engineering is also used in the agricultural industry, which has benefitted
tremendously from the development of transgenic plants. Thus there is a great interest in
engineering genome editing tools to aid in further developments. To this end the HE
4Figure 1.1. Mechanisms of DNA DSB repair provide opportunities for 
genome editing. The three cannonical modes of DNA DSB repair are shown 
above. NHEJ and MMEJ both begin with resection of the 5' ends created by the 
DSB, but their mechanisms diverge thereafter. In NHEJ, digestion of the 3' 
overhangs created by resection creates blunt ends, which are ligated together. In 
MMEJ, regions of microhomology between the 3' overhangs are brought 
together, excess 3' ends are removed, and missing nucleotides are filled in 
adjacent to the microhomologous region. HDR uses a donor template with 
homologous regions on both sides of the DSB. The region adjacent to the DSB 
is replaced by replicating the donor template.
5 I-CreI has been re-engineered to generate transgenic varieties of  maize by effecting
insertions and deletions at a defined site within immature embryos12. Further, multigene
plant  transformation  vectors  have  been  developed  that  employ  a  cloning  system
composed of zinc-finger (ZF) nucleases (ZFNs) and HEs13, and plant viral vectors have
been used to deliver endonuclease genes14.
The  medical  and  pharmaceutical  industries  have  benefited  from  genetically
engineered  organisms  that  produce  therapeutic  proteins,  such  as  human  insulin  and
human growth hormone15. Genetic engineering is also a promising avenue of research
for the field of renewable energy. Genetically engineered photosynthetic algae present
the unique opportunity to harness solar energy and convert it directly into biofuels16, or
value-added products17. One interesting offshoot of genetic engineering is its impact on
computer technology. Bacterial chromosomes were harnessed to generate a DNA-based
retrievable data storage unit18,19 and to effect digital control of gene expression, which
are first steps towards a biological computer20.
 Genetic engineering is also being investigated for its potentially transformative
effect  on  population  genetics  and  allelic  frequencies.  In  one  application,  potentially
disease  carrying  mosquitoes  of  the  species  Anopheles  gambia were  engineered  for
reduced fertility by targeting their genome with a synthetic genetic element containing
the  HE I-SceI21,22.  Similar  results  were  observed using  the  I-PpoI  HE gene in  male
mosquitoes23. Related studies of the propagation of malaria by mosquitoes predict that
transmission of a HE gene in this manner would reduce the incidence and spread of
malaria24.
 
61.1.3 Genome Editing in Gene Therapy
Gene therapy is  in situ or  ex vivo DNA correction or manipulation to restore a
healthy  state  to  a  diseased  organism.  Such  corrections  could  ameliorate  countless
hereditary disorders, or eliminate core components of a provirus. The promise of much
needed medical advancements has spurred countless attempts to apply genome editing
techniques  to  human  disease.  The  more  promising  applications  involve  monogenic
diseases  that  can  be  treated  ex  vivo,  such  as  blood  disorders,  skin  ailments,  and
immunodeficiencies25.  Notably,  a  successful  proof  of  concept  treatment  of  the
monogenic  immunodeficiency,  ADA-SCID  was  demonstrated  using  using  viral
vectors26. However, off-target gene integration led to leukemia in five patients, and one
patient's death. Thus, engineered genome editing tools with more precise targeting are
needed27.
Some preliminary success in using genome editing tools for gene therapy have
been achieved using engineered recombinases. Recombinases are a class of enzymes
that are capable of translocating genetic material between a DNA vector and a genome
(see §1.2.1). This ability to move genetic material has been exploited in mice to develop
a  number  of  potential  treatments  for  diseases  such  as  hemophilia28,  muscular
dystrophy29,  Junctional  epidermolysis  bullosa30,  peripheral  vascular  disease31,  and
rheumatoid arthritis32.  Some success has also been had with recombinases in human
cells,  such  as  the  genetic  correction  of  dystrophic  epidermolysis  bullosa  in  primary
patient cells33, and the reprogramming of somatic cells to pluripotency34, 35.
A lot of work has gone into developing gene therapy approaches for treating HIV
infection. In one such study designer endonucleases were coupled  in trans with DNA
7end-processing  enzymes  to  bias  DNA  repair  towards  using  HDR36.  In  one  such
application  a  3′  repair  exonuclease,  Trex2,  was  overexpressed  along  with  ZFNs,
transcription  activator  like  effector  nucleases  (TALENs),  or  an  engineered  I-CreI
LAGLIDADG HE (LHE). The result was an improved yield of targeted gene disruption
in several different cell lines. In particular, the I-CreI based approach effected a seven-
fold  increase  in  gene  disruption  of  the  endogenous  HIV  coreceptor  CCR536.
Furthermore, the ZFN-based approach is now in clinical trials37. Other approaches have
sought to eliminate the virus in its proviral phase. The LHE I-AniI has been shown to
cure cells of latent HIV infection by mutagenising key proviral sequences38.
Progress  has  also  been  made  in  developing  therapeutics  for  other  human
diseases. An engineered I-CreI LHE was developed that could target and correct a defect
in  the XPC1 gene of  patients  with Xeroderma pigmentosum39,40.  In  a  similar  effort,
another engineered I-CreI LHE was developed to target the RAG1 gene in SCID41,42. In
another example, an engineered I-CreI LHE was developed to correct a dystrophin gene
defect underlying Duchenne muscular dystrophy43.
Therapies built  around genome editing tools are still  in their  infancy25,44,  and
there are a few main obstacles to their application. For example, many of these therapies
operate by genetically modifying a subset of the patient's (or a compatible donor's) cells
in  culture,  and  transplanting  them  into  the  relevant  tissue,  where  they  multiply  to
supplant the diseased cells; however, such a strategy is impossible in non-dividing cells.
Furthermore,  genome  editing  with  nucleases  relies  upon  HDR  for  the  insertion  or
replacement of genetic material; however, HDR is downregulated in many terminally
differentiated cells, such as cardiomyocytes45, or neurons46. Another complication arises
8from off-target DNA cleavage, which can cause unwanted genetic modifications. Take
for  example  the  observation  of  Cre  and  φC31-mediated  recombination  of  off-target
pseudo-recombination  sites47,48,  which  has  been  shown  to  lead  to  deletions  and
chromosomal  re-arrangements  in  cultured  cells49-51 and  mice52.  Additionally,  DNA
damage has been observed at sites of ZF recombinase (ZFR)-mediated recombination53.
Some of these modifications may convert proto-oncogenes to oncogenes, and lead to
cancer, as was the case with one notable attempt to treat ADA-SCID with gene therapy
using  a  viral  vector  and  recombinase27.  However,  protein  engineering  approaches
provide an opportunity to develop new tools for genome editing that are more selective,
robust, and reliable.
1.2 Tools for Genome Editing
 As a result of the many promises of the field of genetic engineering and gene
therapy presented above, a great deal of interest has been poured into developing tools
to  advance  the  field  of  genome  editing1,2,54-58.  These  tools  are  typically  engineered
variants of enzymes that effect site-specific cleavage, such as recombinases, integrases,
HEs,  or  restriction  endonucleases  (REs).  These  engineered  enzymes  may  also  be
coupled  to  proteins  whose  native  function  requires  sequence-specific  recognition  of
DNA, such as ZFs or TALEs. Each of these engineered enzymes has its own strengths
and failings, leading to the great diversity of genome editing tools – potential or proven
(e.g. TALENs, and CRISPRs). However, due to the caveats described above, none of
these  tools  have  proven  themselves  sufficiently  reliable  in  a  clinical  or  therapeutic
context.  Efforts  to  develop  a  robust  therapeutic  genome  editing  tool  benefit  from
9concurrent  development  of  a  variety of  tools,  each  with  unique  characteristics.  The
following sections describe those tools that are currently under development, and which
may yet provide a robust therapeutic genome editing tool. 
1.2.1 Recombinases/Integrases
 Recombinases (also known as integrases) are a class of enzymes responsible for
integration  and  excision  of  viral  genomes,  activation  of  developmental  genes  and
transposition  of  mobile  genetic  elements  (MGEs)59.  Identification  of  recombinase
minimal nucleotide target sequences has permitted their use in metabolic and genetic
engineering, and synthetic biology. In this capacity,  recombinases have been used to
create  gene  knock-outs60-62.  Their  high  site-specificity  also  makes  them  useful  for
targeted integration and excision of transgenic elements and selectable markers63-66.
1.2.2 Restriction Endonucleases
Recombinant type II REs are instrumental to molecular biology; both for their
usefulness in molecular cloning, and because of their high-fidelity and straightforward
reaction conditions, requiring only Mg2+ as a cofactor67. REs were initially discovered
during  investigations  of  viral  restriction,  when it  was  observed that  viral  DNA was
eliminated from a bacterial cell68. Further investigation revealed that REs were targeting
specific 4-8 bp palindromic DNA sequences and methylation states to eliminate non-self
DNA.  Indeed,  REs  are  highly  sequence-specific,  as  evidenced  by  intolerance  to
substitutions in their target. For example, plasmid pAT153 has 12 EcoRV sites that differ
from the cognate  target  sequence by a  single  nucleotide,  and the  best  of  these was
10
cleaved 6 orders of magnitude less efficiently (kcat/Km) than the cognate target69. Further,
a typical type II RE binds its cognate target with nano- to picomolar affinity, but against
a non-cognate target, affinity is only in the μM range70.
 One consequence of such high sequence specificity is the difficulty of making
altered specificity type II RE mutants. Attempts to generate novel specificities in type II
REs by substituting amino acids used in base-specific interactions proved futile,  and
tended to lead to reduced activity without significantly changing specificity71-73.  This
outcome was explained by the role to which REs have evolved. REs must retain high
specificity  against  a  single  target,  and  so  have  redundant  means  of  recognition,
conferred  by an extensive  network  of  intramolecular  contacts  and bound waters74-78.
Furthermore,  crystal  structures  provide  only ground-state  depictions  of  the  enzyme-
substrate (ES) complex, and gross amino acid substitutions often leave functional groups
at  the wrong distance or orientation.  However,  some facile  specificity changes  have
been identified, but they required at least a pair of amino acid substitutions, one for each
nucleobase in the basepair79.
Despite being highly sequence-specific, most REs are fundamentally unsuitable
for genome editing. A given RE would be expected to cleave every 4h bp, where h is the
length of the cognate site. Consequently, widespread cleavage would be expected in a
genomic context. For example, the human genome has ca. 50,000-13,000,000 sites of 8-
4 bp, respectively. However, the type IIS RE FokI has proven invaluable to genome
editing efforts in that it has a non-specific ND that has been conjugated to DBDs to
generate chimeric nucleases, described in greater detail below (see §1.2.3 and 1.2.4).
Additionally,  type  V  REs  are  a  more  recently  discovered  family  of  REs,  and  are
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uniquely suited to genome editing.  Type V REs are components of the CRISPR/Cas
restriction system, which uses sequence complementarity to guide RNAs to target DNA
cleavage, and is the topic of the next section.
1.2.2.1 CRISPR/Cas9
First – and unknowingly – observed in 1987 during sequencing of the E. coli iap
gene80,  it  wasn't  until  2005  that  CRISPRs  were  recognised  for  what  they  were;  a
bacterial defence system81-83. With further investigation, the full process was eludicated84,
85. Foreign DNA sequences are incorporated into a CRISPR locus for later recognition.
These sequences are then transcribed as crRNAs, or “guide RNAs”, which are ssRNAs
that are bound by proteins expressed from CRISPR associated (cas) genes to cleave
foreign DNA complementary to the crRNA. Further study of CRISPR function revealed
that in type II CRISPR immune systems cleavage of DNA targeted by the crRNA could
be effected by a single gene product, Cas986. Cas9 binds another RNA, tracrRNA, which
itself binds a complementary region of the crRNA in order to recruit crRNAs to Cas9.
By merging the crRNA and tracrRNA into a single chimeric guide RNA, or sgRNA,
cleavage could be accomplished by a single RNA-enzyme pair87. The direct method of
targeting through complementary basepairing and the simplicity of a two component
sgRNA-Cas9 system lended itself to genome editing approaches. Since the year 2013,
papers have been published demonstrating genome editing with the CRISPR/Cas9 in
human cells, zebrafish embryos, and bacteria88. 
1.2.2.2 FokI Nuclease Domain is Useful for Genome Editing
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 FokI is a modular type IIS RE, comprised of a site-specific N-terminal DBD and
non-specific C-terminal ND that is functional as a dimer89,90. Although REs are generally
unsuitable  for  genome editing  for  the  reasons  discussed  above,  the  FokI  ND alone
provides an alternate strategy for targeting a specific genetic locus. FokI can be attached
to a pair of DBDs, each flanking a chosen target site to confer endonuclease function
against that site. DBDs that have been successfully used include ZFs and TAL effectors,
which are described in further detail below. 
 
1.2.3 Zinc-finger Nucleases
Motivated by failed attempts at re-engineering REs, Chandrasegaran et al. took
the nonspecific  ND from FokI and combined it  with a  ubiquitous  DNA recognition
domain, ZF protein, as the DBD91. Fusions of these domains functioned as endonuclease
with a target sequence defined by the ZF-DBD. The variety of ZFs, each recognising a
distinct  trinucleotide  gave  promise  to  the  approach92.  Indeed,  several  ZFs  could  be
appended to the FokI ND to make ZF arrays (ZFAs)93. Each ZFA can be designed to
target a sequence of 9-12 bps, meaning that a complete FokI dimer recruited by a pair of
ZFAs can target a site defined by 18-24 bp. This extent of sequence recognition provides
a potential means to target a single site in a genomic context. However, the trinucleotide
recognition by the ZF proteins proved less stringent than their successor, TALE proteins.
 
1.2.4 TAL Effector Nucleases
The modular approach to defining a target site used for ZFEs was the inspiration
for another class of engineered nucleases, based upon TAL effectors94. Identified from
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Xanthomonas bacteria95, TALEs are proteins comprised of repeating peptides that differ
by only two residues, known as the repeat variable diresidue (RVD)96. These RVDs each
define a single nucleobase in the TALE recognition site, based upon the identity of the
two  amino  acids  in  the  variable  di-residue.  Joined  with  the  FokI  ND,  these  TALE
nucleases provide a straightforward method of targeting any DNA sequence.
1.2.5 Homing Endonucleases
 HEs  are  derived  from  a  class  of  MGE  that  defy  the  laws  of  mendelian
inheritance.  Discovered  in  1970,  HEs  are  unidirectionally  inherited,  owing  to  their
unique method of transmission97. HEs are responsible for catalysing a DSB in a naïve
allele, and co-opting DNA DSB repair pathways to integrate its host intron in a process
termed 'homing' (Figure 1.2)98. Since their discovery, HEs have been found in all three
domains of life99, and in different genetic contexts, within group I or group II introns100,
as self-splicing inteins101-103, and as free-standing genes104. 
Evolution of HEs has been guided by two somewhat contradictory forces. On the
one hand, the process of homing requires that HEs be highly site-specific such that they
insert reliably into the naïve allele, which is often a functionally critical gene105, without
causing deleterious mutations. On the other hand, their continued propagation requires
that they be able to target homologous genes in (i.e. “jump” to) other species98. Indeed,
experimental determinations of HE target specificity have found that they bind long
targets  (12-40 nts),  and  are  thus  highly site  specific,  yet  tend  to  tolerate  individual
substitutions106,107. The ability to  bind long target  sites  in a  site-specific  (if  not  fully
sequence specific manner), and use DNA repair to alter a single genetic locus makes 
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binding & 
cleavage
HDR & insertion
Figure 1.2. Endonuclease homing is a process which relies upon precise 
cleavage and repair, and is responsible for propagation of its MGE. Homing 
is the process by which lateral transfer of a MGE (orange) from one allele 
(turqoise) to another (magenta) is facilitated by the endonuclease which it 
encodes. Once the endonuclease is expressed, it binds specifically to its homing 
site (red) a sequence near the intended MGE insertion-site, and typically induces 
a DSB in a naïve allele. When the MGE harbouring allele is used as a template 
during HDR of the nuclease induced DSB, the MGE becomes incorporated into 
the repaired strand, separating the homing site across the MGE and preventing 
further DSBs.
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HEs a promising platform for the development of tools for genome editing. 
All HEs currently identified fall into one of six families that are named after the
consensus amino acid sequence that defines the family. The six families are HNH, His-
Cys,  PD-(D/E)xK,  EDxHD,  LAGLIDADG,  and  GIY-YIG1.  Although  each  of  these
families share the above-mentioned characteristics of HEs, only two of these families
have been exploited for genome editing applications, LHEs and GIY-YIG HEs.
1.2.6 LAGLIDADG Family Homing Endonucleases
LHEs  (also  known  as  meganucleases)  were  the  first  family  of  HEs  to  be
identified, and since their discovery in 1970 they have provided a system to understand
MGEs108. This long history of investigation has produced a wealth of information about
LHE structure and mechanism, including 37 crystal structures to date. LHEs consist of
two  LAGLIDADG  domains  that  are  either  subunits  of  a  dimer,  or  domains  of  a
monomer, that bind the enzyme's 16-26 bp cognate target (Figure 1.3)109,110. The single
active site of LHEs is formed at the interface between pseudo-symmetric LAGLIDADG
domains, and is responsible for cleavage of both DNA strands. It is still unclear if LHEs
as a family require two or more divalent metal ions to effect catalysis, as examples of
both exist in the literature111,112.
 
1.2.7 Engineered LHEs for Genome Editing
LHEs provide a promising platform for genome editing. Their relatively small
size facilitates expression in the host organism, and extensive structural characterisation
facilitates rational design and targeted mutagenesis.
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Figure 1.3. I-OnuI LHE has a pseudosymmetric dimer of two structurally 
similar domains.  The structure of I-OnuI, like other LHEs, has a striking 2-
fold rotational axis. These domains are nonidentical, and each imposes its own 
distinct substrate sequence preference.
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 Furthermore,  their  two-domain pseudo-symmetric  structure and growing number  of
identified family members supports an intuitive mode of developing LHEs with altered
target  site  preferences  via domain  swapping.  These  characteristics  combined  have
allowed  a  repertoire  of  engineered  LHEs  with  an  extensive  array  of  target  site
preferences to emerge. 
Efforts to engineer LHEs with altered target site preference fall into two broad
categories:  mutagenesis-based  approaches,  and  domain  swapping  approaches.
Mutagenesis-based  approaches  use  directed  evolution,  rational  design  or  computer
assisted  design  to  identify  amino  acids  of  importance  for  binding  or  catalysis  and
substitute one or more of these amino acids to effect a change in specificity. Domain
swapping  approaches  seek  to  first  define  independent  functional  domains  of  a
multidomain enzyme. These domains can then be recombined with functional domains
of other enzymes to produce a chimaera with a new, combined function.
  In  one  example  of  the  mutagenesis-based  approach,  the  LHE  I-OnuI  was
engineered using directed evolution to preferentially target the human MAO B gene4.
The MAO B gene has been implicated in the development of Parkinson's disease, and
MAO B itself is a therapeutic target. Within the MAO B gene there is a sequence that
differs  from the  native I-OnuI target  sequence at  only 5 base-pairs.  The engineered
LHEs were generated by saturating mutagenesis of amino acid positions identified from
crystal  structures  to  be  in  contact  with  those  nucleobases  that  differed  between  the
native and MAO B target site, and selected over several rounds of directed evolution.
Ultimately, an engineered I-OnuI variant named I-OnuI E2 was developed that showed
an ~2.5-fold preference for the MAO B target over the native target site. This engineered
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LHE was later incorporated into a chimaeric fusion with the ND of I-TevI to create a
dual-cutting  endonuclease  that  presented  a  high  frequency  of  site-specific  gene
disruption in mammalian cell culture, without the need for end processing enzymes such
as Trex2113.
In an example of the domain swapping approach, the pseudosymmetry of LHEs
was capitalised on to generate an engineered HE named E-DreI114,115.  The “left” and
“right” domains of E-DreI were derived from two distinct members of the LHE family,
I-DmoI, and I-CreI. The N-terminal domain of I-DmoI and a monomer of I-CreI were
computationally combined, and amino acid substitutions were identified that optimised
the  interdomain  interface.  In  this  way,  the  authors  generated  a  chimaeric  HE  that
targeted a combined target  site with an enzymatic efficiency on par with the parent
enzymes.  Building on the success of E-DreI, 30 chimaeric LHEs were generated,  of
which 14 displayed catalytic activity116.
 
1.2.8 GIY-YIG Homing Endonucleases: I-TevI
GIY-YIG HEs possess  traits  consistent  with  the prototypical  GIY-YIG HE I-
TevI. I-TevI has an N-terminal GIY-YIG ND and a C-terminal helix-turn-helix (HTH)
DBD  tethered  by  a  flexible  linker  region  (Figure  1.4A)5,  making  I-TevI  inherently
modular. A crystal structure of the C-terminal DBD with substrate, coupled with affinity
assays reveals that the DBD is responsible for most of the enzyme's binding affinity and
sequence recognition117,118.  Functional characterisations have identified the N-terminal
ND as being responsible for cleavage118, where it acts as a monomer to target sites based
upon both distance from the DBD and its own limited sequence specificity119. Cleavage 
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TATCAACGCTCAGTAGATGTTTTCTTGGGTCTACCGTTTAATATTGCGTCA
A
B
Figure 1.4. Structure of I-TevI HE and its cognate target site convey 
corresponding modularity. The structure of I-TevI (panel A) is composed of an 
N-terminal ND (green, from PDB 1MK0), connected via a flexible linker to a C-
terminal DBD (both in blue, from PDB 1IJ3). A portion of the I-TevI linker 
region did not form a single ordered structure in the cocrystal, and is thus shown 
diagramatically as a dotted grey line. Similarly, the cognate homing site (panel B) 
can be divided into the cleavage motif (green), which is connected by a spacer to 
the I-TevI binding site (both in blue).
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is effected in two sequential nicking reactions, where the bottom strand is nicked first in
a metal independent reaction, prior to the Mg2+-dependent nicking of the top strand119.
The I-TevI ND recognises a five-basepair cognate cleavage motif, 5' – CAACG – 3'.
Further investigation of the I-TevI ND cleavage profile revealed that it recognises the
more general cleavage motif, 5' – CNNNG – 3'120, equivalent to ~6 bits of information.
There is no clear pattern for cleavage of the 64 possible triplets (NNNs). Although some
NNNs are not cleaved, promiscuity abounds, and cleavage efficiency spans three orders
of magnitude113.  The lack of direct correlation between NNN sequence and cleavage
efficiency  indicates  that  indirect  readout  is  likely  playing  a  role  in  cleavage  motif
recognition. 
 Investigation of I-TevI is hampered by the inherent toxicity of this enzyme to E.
coli cells121, which precludes traditional overexpression and purification techniques. For
this reason, studies of the I-TevI ND have been carried out using fusions of the ND with
other  DBDs6 –  analogous  to  FokI-based  nucleases  –  or  by  extrapolating  from
experiments done using a close relative of I-TevI, I-BmoI122.
The structural and functional modularity of I-TevI is evident in its modular target
site (Figure 1.4B)123, which is consistent with the view that the ND alone is responsible
for catalysis and is a contributor to cleavage motif sequence recognition. Although the
low binding affinity and dynamic nature of its mechanism118 make the I-TevI ND less
accessible  to  characterisation  by  techniques  that  rely  upon  stable  interactions  (e.g.
crosslinking, STD-NMR, FRET, SPR, x-ray crystallography, or ITC), important residues
have been identified by mutagenesis. R27118, H40123, and E75124 have all been identified
as important catalytic residues, as I-TevI R27A or E75A were unable to effect DSBs,
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and H40Y had reduced activity. The function of these and other residues have also been
predicted  by  homology,  using  GIY-YIG  NDs  that  exist  in  a  variety  of  enzymes,
including  I-BmoI,  UvrC,  Eco29kI,  and  Hpy188I  (see  below,  Figure  3.5).  Although
indirect methods have fostered a greater understanding of the I-TevI ND, the knowledge
required for re-engineering is currently incomplete.
As alluded to above, the I-TevI ND domain and its associated specificity can be
ported  to  other  DBDs.  This  ND  has  been  successfully  paired  with  Zinc  fingers6,
TALEs125, 126, and LHEs6, 113. The value of such portability has already been demonstrated
by the extensive use of the FokI ND, described above. In the case of a combined I-TevI
and LHE chimaera (MegaTev),  the  combined cleavage activities  and specificities  of
these  two  enzymes  together  has  been  demonstrated  to  efficiently  effect  target  gene
disruption113. Furthermore, the chimaeric MegaTev is not as toxic to  E. coli as I-TevI,
and can be overexpressed and purified113. For these reasons, I used a fusion of the I-TevI
ND to a catalytically inactive variant of the LHE I-OnuI – where it functions as a DBD
– to generate the results described in this thesis.
The I-TevI ND possesses a number of characteristics that make it a potentially
useful component of genome editing tools. As mentioned above, the ND is active as a
monomer,  which  simplifies  engineering  constraints,  and  it  has  its  own  sequence
specificity, which reduces off-target cleavage. However, the use of this ND in genome
editing is restricted by its limited specificity, driving the need for I-TevI ND variants
with altered sequence specificity. This is made challenging by the lack of information
about  the  exact  source  of  its  cleavage  specificity.  Further,  rational  design  is  made
impossible by the lack of a co-crystal of the holo-enzyme, complete with substrate, thus
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directed evolution approaches are indicated. 
1.3 Towards Engineering and Understanding the I-TevI ND
1.3.1 Hypothesis & Objectives
As described above, the I-TevI ND is highly sequence tolerant, likely stemming
from the use of indirect readout to recognise and cleave the 5' – CNNNG – 3' cleavage
motif.  Understanding  the  mechanism by which  readout  is  conveyed  by I-TevI  will
facilitate engineering of this portable ND. Thus, my null hypothesis is that readout of the
cleavage motif is not conveyed by residues of the ND, and that altering these residues
will not alter the cleavage profile of the I-TevI ND.
To test this hypothesis I pursued several research objectives:
Objective 1) Create a library of I-TevI ND mutants using random mutagenesis.
Objective 2) Use a directed evolution approach to selectively identify mutants that 
are active on cleavage motifs that the wild-type I-TevI ND is not.
Objective 3) Identify which individual mutations or combinations thereof are 
responsible for conferring said cleavage activity.
Objective 4) Overexpress, purify, and kinetically characterise a mutant MegaTev 
with a new cleavage activity to determine its cleavage profile.
1.3.2 Scope & Relevance
My  goal  in  this  thesis  was  to  identify  mutations,  and  thus  amino  acid
substitutions of the I-TevI ND that alter its cleavage profile. I expect that the positions of
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these  substitutions  correspond to those  that  convey indirect  readout  of  the  cleavage
motif.  By identifying amino acids that are putatively involved in conveying indirect
readout I hope to provide a means to better understand and potentially engineer I-TevI
NDs with a cleavage profiles that are orthogonal to that of the wild-type ND. Such NDs
could contribute to the development of a therapeutic genome editing tool.
The following chapter (Chapter 2) details the methods I used to carry out my
experimental objectives. Chapter 3 recounts the results of my selections, the mutants I
identified  and  their  characterisation  in  vivo. Further,  it  described  the  in  vitro
characterisation  of  the  I-TevI  ND  triple  mutant  T3,  which  was  revealed  to  have  a
significantly relaxed cleavage specificity. Chapter 4 discusses the implications of the
mutations  that  I  have identified with respect  to  previously identified mutations,  and
presents  the  experiments  that  are  now  possible,  and  that  I  intend  to  carry  out  in
pursuance of my PhD. Finally, supplementary figures and tables present the results of
individual  in vivo and  in vitro assays, and specify the bacterial strains, plasmids, and
primers used to complete this work. 
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Chapter 2 METHODS
 All  bacterial  strains,  plasmids,  and  oligonucleotide  primers  are  listed  in
supplementary  Tables  S.1,  S.2,  and  S.3,  respectively.  All  restriction  enzymes  were
acquired from NEB. Unless stated otherwise, small molecule reagents were acquired
from EMD. 
2.1  Construction of Mutagenised I-TevI Libraries 
I-TevI ND mutant libraries were generated using Mutazyme II (Agilent), a mix
of DNA polymerases for error prone PCR. Primers DE-840 and DE-1912 were used to
select the region to be mutagenised.  0.2 ng of the I-TevI ND was then mutagenised
throughout  amino acids  10 – 95 under  manufacturer-defined conditions  for  30 PCR
cycles. Mutagenesis was repeated as before for another 30 cycles in a fresh reaction to
further  increase  the  extend  of  mutagenesis  before  end-point  PCR  with  Taq DNA
polymerase (NEB) was used to amplify the mutant ND sequences. A truncated I-TevI
linker  region  (residues  96-169)  was  amplified  using  end-point  PCR  with  Taq and
primers DE-1424 and DE-1045, and then combined with the I-TevI ND mutant library
using  splicing  by overlap  extension  (SOEing)  PCR with  Phusion DNA polymerase
(Thermo Scientific) and primers DE-840 and DE-1045. The ND mutant library with
wild-type linker was digested with NcoI-HF and BamHI-HF and ligated using T4 DNA
ligase (NEB) into the PciI and BamHI sites of an I-OnuI E1 E22Q with hexahistidine
tag  encoding  plasmid,  pACYCOnuE1E22Q(+H).  Negative  ligation  controls  were
conducted by omitting insert in a parallel ligation set up. Complexity of library was
determined based upon difference between colony count on ligation plate, and colony
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count on the negative ligation control. In the final construct, the library of chimaeric
MegaTevs with  mutant  NDs,  was downstream of  a  T7 promoter/lac operator  and a
ribosome binding site, and upstream-adjacent to a sequence encoding residues 4-307 of
I-OnuI E1 E22Q with a C-terminal hexahistidine tag.
2.2 Directed Evolution and Selection of Variants
Electrocompetent cells for directed evolution were prepared from E. coli strain
BW25141(λDE3) transformed with a pTox plasmid as described previously6. Batches of
electrocompetent  cells  were  tested  for  lack  of  retention  of  the  toxic  plasmid  by
transforming them with 10 ng pACYCDuet-1; batches of cells that displayed survival
greater  than 0.1% under selective conditions (expression of the toxic protein,  Ccdb)
were discarded. Typically, 50 μL of electrocompetent cells were transformed with 10 ng
of plasmid harbouring the I-TevI ND mutant library, and immediately diluted with 500
μL of SOC media for incubation at 37°C with shaking (280 RPM) for an amount of time
that  depended on the  round of  selection  underway.  For  the  first  round of  selection,
cultures were incubated at 37°C for 6 h, while subsequent rounds were incubated for 1
h. 100 μL was diluted and plated as described below for in vivo survival assays. Another
200 μL was removed and diluted into two separate 5 mL aliquots of lysogeny broth (LB)
media: a “non-selective” media with chloramphenicol (25 μg/mL) alone, and a selective
media that also contained arabinose (10 mM). The diluted cultures were incubated at
30°C with shaking (280 RPM) for 18 h before being harvested by centrifugation and
their plasmids isolated using a plasmid miniprep kit (Bio Basic) for subsequent rounds
of selection.
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After two rounds of selection, those populations of mutant NDs that showed a
measureable increase in survival were PCR amplified with primers DE-840 and DE-
1045. The amplified DNA was treated with DpnI (NEB) to destroy any remaining round
2  plasmids,  digested  with  NcoI-HF  and  BamHI-HF,  and  religated  back  into
pACYCDuet-1(PciI).
Round  4  survivors  were  sampled  by  picking  five  colonies  from  the
corresponding selective plates, and incubating them overnight in 5 mL LB media with
chloramphenicol (25 μg/mL) at 37°C, for subsequent plasmid isolation with a plasmid
miniprep kit. 
2.3 in vivo Survival Assays 
Electrocompetent cells harbouring pTox plasmids were generated as described in
the previous section, and were typically transformed with 50 ng of plasmid harbouring a
MegaTev with a mutant ND, and immediately diluted with 500  μL of SOC media for
incubation at 37°C for 1 h. Cultures were diluted 1/1, 1/10, 1/100, 1/1000 and 1/10000,
and 100 μL of diluted culture was plated on selective (chloramphenicol [25 μg/ml] and
arabinose [10 mM]) and non-selective (chloramphenicol  [25  μg/ml])  LB media,  and
incubated  for  20  h  at  37°C,  and  colonies  counted.  Data  quality  was  improved  by
discarding plates that did not meet the following criteria: colonies were only counted on
those plates that had >10 colonies (preferrably hundreds), or >0.1 % survival, whichever
was greater. 
 
2.4 Construction of I-TevI Nuclease Domain Mutants
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Construction  of  I-TevI  NDs  that  were  not  identified  by  sampling  round  4
survivors was typically achieved by SOEing together fragments of previously identified
I-TevI ND mutants using Phusion DNA polymerase. To generate K26R, primers DE-840
and DE-1912 were used to amplify the ND of K26R Q158R from amino acids 1 to 95,
the wild-type linker region of I-TevI was amplified using primers DE-1045 and DE-
1424,  and  these  two  regions  were  joined  using  SOEing  PCR as  above  for  library
construction. Similarly, K26R T95S Q158R was made by combining the ND from K26R
T95S and the linker from Q158R. To generate K26S mutants, a pair of complementary
primers with single basepair mismatches to the wild-type I-TevI ND sequence installed a
K26S mutation. These primers were used in combination with primers DE-840 and DE-
1045 to construct each of the K26S mutants. A similar strategy was used to restore T95S
to T95 by amplifying the I-TevI ND with primers DE-840 and DE-2167, and combining
it with the linker sequence as above in order to generate the single mutants C39R, and
I86V.
2.5 Purification of Chimaeric MegaTevs
2.5.1 Overexpression of Chimeric MegaTevs in E. coli 
 Plasmids harbouring MegaTevs comprised of either a wild-type I-TevI ND or
the T3 ND were transformed into ER2566 E. coli cells (NEB), plated on LB media with
chloramphenicol (25 μg/mL), and incubated for 18 h at 37°C. A single colony per plate
was picked and used to inoculate a 20-mL LB culture (with 25 μg/mL chloramphenicol),
which was incubated at 37°C for 4-6 h before being diluted into 1 L LB culture (with 25
μg/mL chloramphenicol) and grown to OD600 = 0.8. The culture was then chilled on ice
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for 30 min, and 1 mL of 1 M isopropyl β-D-1-thiogalactopyranoside (IPTG) was added
to induce enzyme expression, before being incubated for a further 13 h at 15°C. The
cells were then harvested from the culture (now at OD600 of 1.1-1.4) by centrifugation
(4000 ×g, 10 min), and the pellet collected and stored at -80°C for 16-24 h.
2.5.2 Chromatographic Purification of Chimaeric MegsTevs
The cell pellet was resuspended into 35 mL of binding buffer (20 mM Tris·HCl
[pH 8.0], 500 mM NaCl, 5% (v/v) glycerol, 10 mM imidazole) containing a protease
inhibitor  mix  (1/20th of  a  cOmplete™ protease  inhibitor  pellet  [Roche,  added  as  a
suspension of pellet  in  ddiH2O], per  gram of  cell  pellet). Cells  were then sonicated
(power 5, 50% duty cycle, pulsed mode, 5 × 20 pulses), and subjected to centrifugation
(20,000×g,  15 min)  to  separate  the  cell  pellet  from the soluble fraction,  which  was
removed and applied to a His-Bind column (Amersham). The column was then loaded
with a procession of buffers: ~45 mL of binding buffer, 15 mL of wash buffer (binding
buffer with 50 mM imidazole), and 5 mL of elution buffer (binding buffer with 300 mM
imidazole). The final 5 mL of eluate was dialysed (10,000 Da molecular weight cutoff
(MWCO) [Spectra/Por]) against 500 mL storage buffer (20 mM Tris·HCl [pH 8.0], 500
mM NaCl, 5% (v/v) glycerol, 1 mM dithiothreitol [DTT]) for 6 h at 4°C, before the
buffer  was  replaced,  and  dialysis  continued  for  a  further  12  h.  In  the  case  of  the
MegaTev  with  a  wild-type  ND,  aliquots  and  frozen  at  -80°C;  these  aliquots  were
typically active for over a month when stored in this fashion. In the case of MegaTev
T3, the dialysed stock was kept at 4°C and used within a week. 
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2.5.3 Determining MegaTev Quality and Quantity
All  MegaTev  purifications  were  followed  by  electrophoretic  separation  to
determine the purity of the aliquots before the concentration of MegaTev is quantified.
The  concentration  of  MegaTevs  in  solution  was  determined  by  measuring  the  UV
absorbance of the solution at 280 nm (A280) and comparing it to the predicted extinction
coefficient (ε280) of the chimaeric MegaTev (67380 M−1∙cm−1). Predicted ε280 values were
calculated  using  the  “ProtParam”  tool  on  the  ExPASy  website
(http://web.expasy.org/protparam/)  assuming  no  disulfide  bonds.  The  precise
concentration was determined using the Beer-Lambert-Bouguer law127-129 (eqn 2.1; c is
the  molarity,  b  is  the  pathlength  [in  cm]).  It  was  assumed that  the  only significant
protein component in solution was MegaTev, on the basis of the SDS‒PAGE results
(Figure 3.7, below).
 (2.1)
2.6 Barcode Assays and Kinetic Characterisation of Chimaeric MegaTevs
 Barcode assay substrates were prepared by using pTox as template with a pair of
flanking primers equidistant from the cleavage motif (see supplementary Table S.3), in
end-point PCR. Substrates of 2200, 1900, 1600, or 1320 bp were made, and combined
into a single reaction. Substrates contained a 42 bp MegaTev target site comprised of a 5
bp cleavage motif, a 15 bp spacer from the I-TevI native target, and a 22 bp I-OnuI E1
target sequence from the human MAO B gene. The cleavage motif was placed such that
substrates would be cleaved in half to create two equally-sized products. Unreactive pre-
c = A280 / ( b·ε280 ) 
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mixtures were prepared on ice, and were comprised of 5 nM of each substrate, 250 nM
enzyme, and cleavage buffer (50 mM Tris·HCl pH 8.0, 100 mM NaCl, 1 mM DTT, 5%
glycerol).  An aliquot  of  pre-mixture  was  removed immediately prior  to  starting  the
reaction by adding 2 mM MgCl2,  and  incubating at  5°C for  30 min.  Aliquots  were
removed from the reaction mixture at 1, 2, 4, 10, and 30 min time-points (although for
practical purposes some aliquots were removed at 11 or 13 min instead of 10 min), and
quenched by the introduction of ethylenediaminetetraacetic acid (EDTA) and sodium
dodecylsulphate (SDS) (final concentrations of 83 mM, and 8.3%, respectively). Time-
points were resolved using agarose gel electrophoresis in TBE (100 mM Tris base, 100
mM boric acid, 2 mM EDTA [pH 8.0]) and spot densitometry was used to measure the
quantity of substrate remaining in the reaction, and the quantity of product formed. The
intensity  of  the  corresponding  substrate  and  product  bands  at  each  time-point  are
summed, and normalised to the to the intensity of the substrate band at  t  = 0 (forcing
mass balance). The fraction of substrate remaining (fS) is then simply the ratio of the
normalised substrate band intensity to the initial intensity. Triplicate values were plotted
as fractions of substrate remaining at each time-point, and fit by non-linear regression to
a first-order decay curve (eqn 2.2, where fS is the fraction of remaining substrate, m1 and
m2 correct for a non-zero baseline or non-unity starting condition, respectively, m3 is the
kapp in reciprocal minutes, and t is the amount of time passed, in minutes). The apparent
first-order rate constant of decay (kapp) was normalised to  kapp for the native cleavage
motif decay curve, and reported as relative kapp. 
 (2.2)fS = m1 + m2 -m3t 
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2.7 Sequencing of MegaTev T3 Cleavage Products
 Barcode  assay  substrates  harbouring  position  1  substitutions  or  the  native
cleavage motif were digested with MegaTev T3 for 1 h at 37°C, substrates were isolated
from enzyme using a PCR cleanup kit (Bio Basic), and submitted for Sanger sequencing
with one of two flanking primers to obtain the sequence of the top strand (DE-410) and
bottom strand (DE-411). 
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Chapter 3  RESULTS 
3.1 Mutagenesis, Genetic Selection, and Isolation of I-TevI Nuclease Domain  
Mutants
My first research objective was to create a library of I-TevI ND mutants, with the
goal of isolating mutants with activity on cleavage motifs that are poor substrates for the
wild-type enzyme. To accomplish this objective, I first generated a library of I-TevI ND
mutants using an end point PCR technique that makes use of a mix of engineered DNA
polymerases that ensure an equal proportion of each mutation (e.g. A→C, G, or T).
I wanted to ensure that the library was of sufficient complexity to contain all
possible single amino acid substitutions at every position of the ND (20 amino acid
possibilities for each of 86 positions from 10-95, or 1720 single amino acid substitutions
in total). The complexity of the initial library was assessed in two ways: by the number
of successful transformants made with the library, and by the number and variety of
mutations found therein. E. coli BW25141(λDE3) were transformed with the MegaTev
ND mutant library and a subset were plated on LB media with chloramphenicol (25
μg/mL). After an 18 h incubation at 37°C, colonies arising from this subset of the full
culture were counted, and their number extrapolated to the full culture volume. Based
upon  the  number  of  colony  forming  units,  the  library  was  estimated  to  contain
approximately 70,000 cfu. Six of these colonies (LIB-1-LIB-6) were chosen at random,
grown overnight, and harvested to isolate their pENDO plasmids, which were sequenced
(Figure  3.1).  One  of  the  sequenced  plasmids  appeared  to  have  undergone  an
insertion/deletion  reaction  (LIB-4),  and  as  a  result,  ~90% of  its  sequence  had been
frameshifted; this sequence was excluded from further analyses. The other sequences 
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Figure 3.1
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Figure 3.1. PCR with Mutazyme II Consistently Mutates the I-TevI Nuclease 
Domain. Sequences of six clones from the the mutagenised nuclease domain library 
(LIB-1 – LIB-6) are shown above, amino acid sequences on the left, and nucleotide 
sequences on the right. In each of the six NDs there was a single, double, or triple 
amino acid substitution. An indel in LIB-4 has resulted in a frameshift mutation that 
has affected almost all of the amino acid sequence.
35
were  each  revealed  to  have  1-4  amino  acid  substitutions,  either  transversions  or
transitions, as summarised in Table 3.1 and 3.2.
A ratio of transversions and transitions as close to 2:1, but certainly greater than
1:1 was considered important because there are twice as many codons available through
transversions, and thus a greater set of possible mutations at a particular amino acid
position. The extent of mutagenesis observed in this sampling of the library yielded a
ratio of transversions to transitions of 1.5:1.
With  a  sufficiently  complex library of  I-TevI  ND mutants  in  hand,  my next
objective was to identify mutants that were active on cleavage motifs that the wild-type
ND is not. This objective was accomplished using a directed-evolution approach, in the
context of the MegaTev chimaeric nuclease. The library of randomly mutagenised I-TevI
NDs was fused via a partial I-TevI linker to a catalytically inactive I-OnuI E1 E22Q and
subjected to multiple rounds of selection and enrichment using a bacterial 2-plasmid
assay, delineated in Figure 3.2. This assay facilitated rapid phenotypic screening of a
library in a stringent, selective system with an easily controlled selective pressure in the
form of a double stranded plasmid DNA-substrate (pTox). pTox harbours a toxic gene
(ccdb, encoding the topoisomerase-inhibiting peptide, Ccdb), which is under arabinose-
mediated metabolic control (using the araBAD promoter). In this system, cleavage of
the target site linearises pTox, which is then degraded by the E. coli RecBCD complex,
allowing growth of cells with an active endonuclease. This selection is bacteriostatic,
not bacteriocidal, because the CcdB toxin inhibits DNA gyrase. Thus, even very limited
cleavage  of  pTox  was  sufficient  to  overcome  the  selective  challenge.  Since  the
selections were done with a library of ND mutants under direct competition, 
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# (%) # (%)
Transitions 6  (0.4) 10 (2.35)
9 (0.9) Nonsense 2 (0.47)
Total 15 (1.5) Total 12 (2.82)
1 (N/A*)
Table 3.1. Survey of Observed 
Nucleotide and Amino Acid Substitutions
Nucleotide
Substitutions
Amino Acid
Substitutions
Missense
Transversions
Indels
*Percent calculations did not include the sequence with an indel
Table 3.2. Survey of mutation rates in sample sequences.
Final
T C A G
In
iti
al
T - 3 4 1 - Identity
C - Transition
A 2 - 2
G 1 2 -
Transversion
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Figure 3.2. Bacterial two-plasmid selection discriminates between sufficiently 
or insufficiently active I-TevI cleavage domains. Plasmids encoding the mutant 
enzymes are transformed into E. coli  harbouring a second plasmid encoding the 
toxic gene ccdB  under the arabinose-inducible BAD  promoter, and a putative 
endonuclease target site. If the target site is cleaved, the plasmid encoding the toxic 
gene is rapidly degraded, and similar growth is observed in the presence and 
absence of arabinose; if, however, the target site is intact, negligible growth is 
observed in the presence of arabinose. By comparing the relative growth under 
selective (+ara) vs. non-selective (-ara) conditions, % survival was determined.
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alleviating  the  bacteriostatic  effect  granted  a  critical  selective  advantage  over  non-
replicating or slowly replicating competitors.  This approach was chosen because the
strongest survivors would be enriched and would dominate the population.
I  expected that  the  mutations  present  in  my library would be more  likely to
broaden  the  cleavage  profile  of  the  I-TevI  ND,  rather  than  fully  eliminate  activity
against the native 5' – CAACG – 3' cleavage motif. Thus, if the library did not retain any
residual activity against the native cleavage motif, then it would have indicated that the
level of mutagenesis was too high, and had led to complete attenuation of ND activity.
Survival assays testing the library against the native cleavage motif revealed that the
library was able to survive (Table 3.3), albeit at a reduced level compared to the wild-
type ND, which has previously conferred 100% survival.
Confident that I had a library which contained active I-TevI ND mutants, I chose
16  substrates  that  have  been  shown  previously  to  be  highly  cleavage  resistant  to
cleavage by the wild-type I-TevI ND113 from the set of all 64 NNNs as the first priority
for extending the versatility of the I-TevI ND through a broadened cleavage profile. I
anticipated that mutations which resulted in cleavage of a poor substrate were likely to
directly  influence  nuclease  activity,  rather  than  result  from indirect  effects  such  as
increased protein stability or expression. The initial library was screened against all 16
poor  substrates  one  by  one  (R1,  Figure  3.3).  Each  screen  required  an  independent
transformation of the library into competent cells harbouring an individual substrate. For
R1 only, freshly transformed cells were incubated in SOC media at 37°C for 6 h, before
selection proceeded for 18 h at 30°C. This generated 16 populations of enriched I-TevI
ND mutants.
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Figure 3.3.  Mutant populations of I-TevI cleavage domains confer survival 
against toxic plasmids harbouring CNNNG cleavage motifs with cleavage 
resistant triplets. After a round of selection on the library (R1), the population of 
survivors against each substrate was isolated, and subjected to a second round of 
selection (R2). Those populations (A-F) that confer a measurable improvement in 
survival over wild-type (WT), were recloned and subjected to two additional 
rounds of selection (R3 & R4).
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In order to further enrich the mutants that cleaved poor substrates, the resulting
16 populations were each subjected to another round of selection against their respective
substrates (R2, Figure 3.3). For this and all further rounds of selection, selection was
made more stringent by incubating freshly transformed cells for only 1 h, rather than 6
h. The survival rate of each population after round 2 was compared to survival of the
wild-type I-TevI ND against the same substrate (e.g. survival rate of population A on 5'
– CAAGG – 3',  compared to survival conferred by the wild-type enzyme against  5' –
CAAGG – 3').  Only those populations  that  showed any observable  improvement  in
survival  over  the wild-type I-TevI  ND (wt,  Figure 3.3) in  R2 were pursued further.
Improvements  in  survival  compared to  the  wild-type  enzyme were often  very clear,
since the wild-type did not survive to any extent. In these cases, survival greater than
0.1%  (i.e. greater  than  background  survival  observed  with  an  inactive  ND)  was
sufficient to merit further rounds of selection. In those situations where the wild-type
enzyme did confer survival to some extent, survival equal to, or greater than the wild-
type  was  deemed  sufficient.  Such  a  lenient  margin  of  success  was  chosen  because
mutation  is  expected  to  reduce  activity  in  general.  Thus  populations  that  were
indistinguishable from the wild-type enzyme in terms of activity would be expected to
also contain individual mutants that were more active than wild-type.
The populations I obtained in R2 could have been the result of mutations outside
of the I-TevI ND (e.g. chance mutations to promoter leading to increased expression of
endonuclease). I wanted to ensure that only mutations to I-TevI were maintained, and so
I recloned the open reading frames (ORFs) containing the I-TevI ND and partial linker
from each population into fresh background vector prior to further rounds of genetic
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selection.
After four rounds of selection (R4), six populations (A-F) were identified that
showed a marked improvement in survival, ranging from 4-fold for population C, to
>370-fold for population F, as summarized in Table 3.3.  I wanted to assess to what
extent these populations had diverged from the initial library, and the wild-type I-TevI
ND. Namely,  I  wanted to know whether or not my directed evolution approach had
selected enzymes that preferred the cleavage motif they were selected against (e.g.5' –
CAAGG – 3'  for population A) over the native cleavage motif  (5'  – CAACG – 3').
Unfortunately, bacterial 2-plasmid assays of R4 populations against the native cleavage
motif  revealed  that  the  native  cleavage  motif  was  still  preferred  by  each  of  these
populations.
Although the R4 populations preferred the native cleavage motif, they displayed
substantial  improvements  in  survival  over  the  wild-type  I-TevI  ND  against  poor
substrates. Thus I wanted to know what mutations were present in these populations that
might  confer  said  survival.  Five  colonies  were  chosen  from plates  of  survivors  on
selective  media  from each  of  the  six  populations  (A-F),  and  their  MegaTev  ORFs
sequenced to identify their mutations. The number of each mutant genotype observed in
each population are tabulated in Table 3.3. One surprising mutation I observed (Q158R)
was outside of the mutagenised ND region of  I-TevI,  and instead was found in the
partial  I-TevI  linker.  Otherwise,  all  mutations  were  observed  within  the  I-TevI  ND
region. Importantly, none of the MegaTev ORFs sequenced contained the wild-type I-
TevI ND and partial linker.
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3.2 in vivo Characterisation of I-TevI Nuclease Domain Mutants
Having isolated several mutant I-TevI NDs, I was interested in understanding
how – and critically if  –  each amino acid substitution is  affecting the ND cleavage
profile. To determine the effect of individual mutations, mutant I-TevI NDs were made
containing single or double mutants from amino acid substitutions identified from the
genetic  selections.  The ability  of  each  of  these  substitutions  to  confer  survival  in  a
survival assay was determined in triplicate, and is summarised as a heatmap of average
survival values in Figure 3.4, and a table of values in supplementary Table S.4.
Because  survival  is  an  indirect  measurement  of  cleavage  activity,  I  was
concerned that the  in vivo survival I had observed might be caused by a mechanism
independent  of  cleavage.  If  substrate  pTox plasmids  did  not  obviate  survival  in  the
presence  of  a  catalytically  inactive  I-TevI  ND,  then  some  cleavage  independent
mechanism of survival could be providing the results I observed. To confirm that the
results I was observing required a catalytically active ND, triplicate negative control
survival assays were conducted using each substrate and a chimaeric MegaTev with a
catalytically inactive R27A ND mutant; no survival greater than 0.1 % was observed.
Each  individual  amino  acid  substitution  conferred  improvement  in  survival
against cleavage-resistant substrates, which was generally enhanced when substitutions
were combined. For example the K26R mutant displays an ~31% survival rate against 5'
– CAAGG – 3'. Similarly, the Q158R mutant displays an ~53% survival rate against 5' –
CAAGG – 3'.  Combined,  the  K26R Q158R mutant  displays  an  ~86% survival  rate
against 5' – CAAGG – 3', and is an example of a combination of mutations that led to an
44
K
26R
 T95S Q
158R
 (T3)
K
26S C
39R
 T 95S
C
39R
 I86V T 95S
I86V T95S
C
39R
 T95S
C
39R
 I86V
K
26R
 Q
158R
K
26S C
39R
K
26R
 T95S
K
26S T95S
Q
158R
T95S
I86V
C
39R
K
26R
K
26S
w
ild-type
Figure 3.4
45
Figure 3.4. I-TevI ND T3 cleavage specificity is a combined effect of individual 
mutations.  Individual mutations that were identified by survival assay screening 
were introduced into the I-TevI ND individually, or in combination, and their ability 
to confer survival in a 2-plasmid assay was assessed in triplicate. pTox plasmids 
harbouring the native cleavage motif, or one of 16 cleavage-resistant substrates, 
differing in their NNN triplet, were used in survival assays as described in the text. 
Values below 1% are marked with an asterisk.
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additive effect on survival. The same combination of mutations resulted in an ~ 23%
survival rate against 5' – CCAGG – 3', despite the observation that K26R has no impact
on survival against that substrate individually, and Q158R has only an ~1.5% survival
rate against 5' – CCAGG – 3'. The observation that Q158R and K26R together have a
greater  survival  rate  against  5'  –  CCAGG –  3'  is  an  example  of  a  combination  of
mutations that led to a cooperative effect on survival. Through a combination of additive
and cooperative effects, the triple mutant K26R T95S Q158R (T3) conferred the highest
survival rates against the broadest range of substrates tested.
Perhaps most promising was the ~100% survival conferred by T3 against a C1T
substitution in the cleavage motif. C1 of the cleavage motif has previously been shown
to  be  necessary  for  cleavage  by  the  wild-type  I-TevI  ND.  This  result  is  the  first
indication  that  mutants  could  be  developed  that  cleave  targets  which  differ  at  this
position of the cleavage motif.
Since  these  amino  acid  substitutions  conferred  enhanced  survival  under  the
conditions described above, they represented putative functionally important residues.
Thus I expected that exchange of these residues with those found at analogous positions
within another  GIY-YIG ND would bestow some of  that  ND's  substrate  preference.
Comparison of the I-TevI ORF with the related GIY-YIG HE I-BmoI, revealed that all
of  the  positions  identified  here  were  also  positions  of  non-identity  with  I-BmoI,  as
depicted in Figure 3.5. Thus, mutants were made that possessed amino acids consistent
with I-BmoI at  these positions (K26S, C39R, & T95S).  Disappointingly,  I-TevI  ND
mutants with these amino acid substitutions fared no better than wild-type against the
substrate containing a CCCCG cleavage motif, which contains an NNN triplet identical
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to the native I-BmoI cleavage motif GCCCG.
3.3 in vitro Barcode Assays
The  triple  mutant  T3  was  able  to  confer  survival  against  a  broad  range  of
substrates that the wild-type I-TevI ND could not. However, these results could have
been explained by other convoluting variables, such as decreased toxicity, increased in
vivo stability,  increased  catalytic  activity,  other  modes  of  pTox  deactivation,  or  a
combination of these effects; thus, in vitro characterisation was indicated. 
 The barcode assay developed by Monnat et al. for rapidly determining HE target
sites22 can be used to assess cleavage of four unique substrates in a single, competitive,
in vitro, kinetic assay,  and is described schematically in Figure 3.6. This assay can be
used to quantitatively determine kinetic constants for individual substrates relative to the
native 5' – CAACG – 3' cleavage motif. For these assays, two I-TevI chimaeras were
overexpressed and purified as described above. The I-TevI chimaeras were comprised of
the first 169 amino acids of I-TevI, comprising the ND and a partial linker region from
either  wild-type  or  T3,  and  a  C-terminal,  catalytically  inactive  I-OnuI  E1  E22Q.
Purifications  resulted  in  active  enzyme of  sufficient  purity  to  proceed  with  in  vitro
assays (Figure 3.7). Although enzyme activity was observed to decline over time (weeks
for the wild-type ND and days for the T3 ND), it was assumed that this did not affect the
relative cleavage of each substrate. 
The I-TevI  ND T3 was assayed  in  vitro against  assorted substrates that  were
predicted to be poor substrates of the wild-type I-TevI ND, and those substrates that
differed from a poor substrate by a single basepair (Figure 3.8, supplementary Table S.5,
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Figure 3.5. Protein sequence alignment of I-TevI and I-BmoI NDs reveals 
key sequence dispairities between these orthologs that correspond to 
mutations identified in selections. Sequences of I-TevI and I-BmoI NDs were 
aligned using Clustal ω. Residues that were identified in selections are marked 
with red asterisks. Additional GIY-YIG domains from Eco29KI, Hpy188I, and 
UvrC are also aligned for reference.
*
**
*
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Figure 3.6. 'Bar code' in vitro  cleavage assay facilitates quantitative 
assessment of mutant I-TevI cleavage domain activity.  Substrates of varying 
length (panel A), each bisected by a unique cleavage motif are combined into a 
single competitive reaction with a Tev-Onu mutant (panel B), started by addition 
of Mg2+, halted by sequestration of Mg2+ by EDTA, and visualised on an agarose 
gel (represented by panel C). The varied length substrates facilitate measuring 
relative cleavage of each substrate. An example of an agarose gel is shown (panel 
D) from which band densities are measured and used to calculate disappearance 
of substrate over time (measured as [St]/[S0] = fS  or fraction of substrate 
remaining), which are plotted and fit with a first-order decay curve to determine 
the rate of decay (panel E).
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and  supplementary  Figure  S.1).  Altogether,  assays  were  conducted  on  34  distinct
substrates,  using  a  50-fold  excess  of  endonuclease  to  ensure  that  substrates  were
saturated  with  bound  endonuclease,  and  thus  only  the  rate  of  cleavage  was  being
measured.  Furthermore, assays were conducted at  5°C to ensure that initial cleavage
rates were slow enough to be measured. Each assay contained a substrate with the native
5' – CAACG – 3' cleavage motif, which was used as an internal standard for the rate of
enzyme  catalysed  substrate  decay  (represented  by  kapp). All  enzyme  activities  are
reported  relative  to  cleavage  of  the  native  cleavage  motif  standard  (relative  kapp).
Although there is no consistent ratio between the wild-type and T3 ND rates of cleavage
for any particular substrate, the T3 ND is generally more promiscuous (Figure 3.8). 
The in vitro results were generally consistent with the in vivo results; increases in
survival  conferred  by  the  T3  ND  were  associated  with  increased  catalytic  activity.
However, there are cases where a small increase in survival rate was associated with a
large  increase  in  cleavage  activity.  For  example,  survival  on  the  5'  –  CGCTG – 3'
cleavage  motif  by  the  T3  ND  increased  to  13%  from  0%  for  the  wild-type.  This
relatively modest increase in survival rate was associated with a nearly 4-fold increase
in relative kapp, from 0.18 for the wild-type ND to 0.73 for the T3 ND. Conversely, there
are also cases where a small increase in cleavage efficiency was associated with a large
increase in survival.  For example,  survival on the 5'  – CAAGG – 3'  cleavage motif
increased from 1.6% for the wild-type ND to 54% for the T3 ND. This pronounced
increase in survival rate was associated with an only 1.3-fold increase in relative  kapp,
from 0.38 for the wild-type ND to 0.51 for the T3 ND. Although cases such as these do
exist, they represent the minority. In the majority of cases, a large increase in survival 
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Figure 3.7. I-TevI chimaeras were isolated from E. coli  ER2566 cells at 
>95% purity.  The results of a typical purification is displayed by the 
polyacrylamide gel, shown above. Uninduced cells express an undetectable 
amount of the I-TevI chimaera (Un), but after induction with IPTG, I-TevI 
chimaera can be observed after lysis and centrifugation of the cells in both the 
insoluble cell pellet (CP) and supernatant (Sn). The I-TevI chimaera is retained 
by a His-Bind column, and is not observed in the flow-through (FT) or after the 
first wash with binding buffer (B). Wash buffer (W) does remove some of the I-
TevI chimaera, but renders the elution (E, or diluted 1/5 as E 1/5) almost 
completely free of non-specifically bound proteins. Complete removal of Ni2+ 
from the column with EDTA reveals that very little I-TevI chimaera remains on 
the column (F), and that the purification consistently yields a protein of the 
predicted molecular weight (54.6 kDa), when compared to prior purification (+) 
and known molecular weight standards (L).
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Figure 3.8
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Figure 3.8. Kinetic assays reveal that the T3 mutant has a distinct cleavage 
profile. Incubation of barcode assay substrates with a chimaeric fusion comprised 
of either the wild-type I-TevI ND or the T3 ND, resulted in a first-order decay of 
said substrates. The apparent first order kinetic constant for this decay (kapp) was 
determined for each substrate, and normalised to the kapp-value for the native 
target site substrate present in each assay. These relative kapp-values are graphed 
for both the wild-type ND and the T3 mutant. The substrates used differed from 
the native target site by either the NNN triplet, or at position 1 of the cleavage 
motif. Further, they are either highly cleavage-resistant substrates used in vivo 
(marked with a red asterisk; e.g. the TGG triplet), or else related to such a 
substrate by a single nucleotide substitution (e.g.  the triplets AGG, or TCG). 
Values that exceed the dashed line at 0.5 roughly correspond to those for which 
survival was observed in vivo.
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 rate conferred by the T3 ND was accompanied by a correspondingly large increase in
relative kapp value, and vice versa. 
Because barcode assays are inherently competitive, any differences between the
substrates  could  be  contributing  to  their  differing  rates  of  cleavage.  Thus  I  was
concerned that the length of the substrates may have influenced my results. Although the
exact mechanism by which the chimaeric MegaTev constructs bind their  substrate is
unknown, one possible mechanism involves a slow DNA binding step, followed by a
rapid sliding of the MegaTev along the DNA helix to find its target sequence, as is the
case for the RE EcoRV130. In such a situation, a longer substrate would be expected to
have an accelerated DNA binding step, ultimately leading to faster cleavage.
 To determine if the length of the substrate had an impact on cleavage efficiency,
the native I-TevI cleavage motif (5'–CAACG–3') substrates were synthesized in each of
the four possible lengths (2200, 1900, 1600, and 1320 bp). These substrates were mixed,
and cleavage monitored,  as  shown in Figure  3.9A.  It  was determined that  substrate
length had a negligible effect on cleavage rate. 
Another consideration for any competitive assay must be the effect of residual
substrates  on  the  rate  of  cleavage of  their  competitors.  This  may be  observed  as  a
cooperative effect, where the cleavage of each substrate is enhanced or attenuated by the
presence of its competitors. To determine if there was any impact of cooperative effects
between multiple enzyme-substrate pairs on cleavage efficiency, a set of substrates were
synthesized that contained a highly cleavage-resistant cleavage-motif 5' – AAACA – 3'
(1A5A) in three lengths (2200, 1600, and 1320 bp) and a native cleavage motif substrate
5' – CAACG – 3' (1C5G) of the remaining length (1900 bp). As shown in Figure 3.9B, 
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Figure 3.9. Cleavage assays were unaffected by the length of substrate used, or 
the concentration of other substrates in the reaction.  Cleavage assays were 
conducted under the same conditions as similar bar code assays used previously. 
Despite being of different lengths 2.2, 1.9, 1.6 or 1.32 kbp, substrates containing 
the native cleavage motif were not cleaved at rates more disparate than standard 
error (A). Further, no effect of uncleaved substrate (C1A G5A [1A5A]) on 
cleavage of the native cleavage motif (1C5G) was observed (B).
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only the native cleavage motif showed any significant decay over the assay period, and
this decay was aptly fit by a first-order decay curve (R2 = 0.98). Despite a large quantity
of residual substrate being present during the full extent of the assay, the decay of the
remaining substrate was not observably perturbed. Although some decay was seen, this
was likely an artifact, considering that none of the other cleavage resistant substrates
were cleaved. The artifact in question is most common when all substrates are present;
each substrate causes an increase in background intensity for the substrate immediately
above it on the gel image. Thus as the substrate containing the native cleavage motif
decays into products, the background intensity of the first cleavage-resistant substrate
declines as well, leading to an apparent drop in intensity over time. Regardless, such
artifacts  were  not  expected  to  have  any effect  on  determination  of  kapp because  the
correction  factors  m1 and  m2 (described  more  fully  in  §  2.6)  compensate  for  this.
Collectively, these experiments show that cleavage is non-cooperative and unaffected by
substrate length. 
 
3.4 Cleavage Site Sequencing
Although promiscuity by I-TevI has already been observed for positions 2, 3, and
4 of the cleavage motif, a position 1 C of the 5' – CAACG – 3' cleavage motif was
previously  determined  to  be  necessary  for  efficient  target  site  cleavage.  Thus,  the
observation  that  the  T3  triple  mutant  aptly  cleaves  C1T  in  vivo,  and  all  position  1
substitutions in vitro was surprising. This promiscuity could be explained by cleavage of
a secondary target-site that is triggered by the absence of C1. To explore this possibility, 
the products of cleavage reactions with T3 and each of these substrates were sequenced
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using the Sanger method. These sequencing data revealed that the cleavage site has not
changed  for any of the position 1 substitutions (Figure 3.10).  The cleavage motif  is
nicked on the bottom strand between positions 2 and 3 of the cleavage motif (Figure
3.10 for.),  and on the top strand between positions 4 and 5 (Figure 3.10 rev.).  It  is
important to note that the  Taq DNA polymerase  used for Sanger sequencing  affixes a
single adenosine to the 3' end of a nascent strand which is apparent in the readouts from
the  upstream  primer  as  an  additional  3'  adenine,  and  on  the  readouts  from  the
downstream primer as a 5' thymine.
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Figure 3.10. The position of substrate nicking reactions of I-TevI T3 are 
unaffected by subsitutions at position 1 of the cleavage motif. pTox plasmids 
harbouring native cleavage motif (C1C [C, D]), or one of three position 1 
substitutions (C1A [A, B], C1G [E, F], C1T [G, H]) were sequenced using 
flanking primers: one upstream of the cleavage motif (for. [A, C, E, G]) and one 
downstream (rev. [B, D, F, H], the reverse complement is shown). Sanger 
sequencing readouts are shown with traces for adenine (green), cytosine (blue), 
guanine (black), and thymine (red). The cleavage motif is given above the 
corresponding region of the readout, with a chevron indicating the predicted 
nicking position. A drop-off in fluorescence intensity is seen in each sanger 
readout corresponding to the predicted nicking positions in all eight cases.
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Chapter 4 DISCUSSION & CONCLUSIONS
Altering the specificity of existing HEs is  central  to any effort  to extend the
versatility of this genome editing platform; however, altering the specificity of HEs has
proven difficult. Typically, success is achieved by separating the HE into 'modules' that
retain their function when recombined with modules from other proteins. In the case of
I-TevI, the ND has been shown to be such a module, and has been ported to numerous
other DBDs; however, the native cleavage specificity of the I-TevI ND is limiting, and
thus installing new specificities are desired. In previous cases, new specificities were
developed  through  a  relaxed  specificity  intermediate.  Further,  installing  new
specificities  is  facilitated  by a  knowledge of  which  amino acids  are  responsible  for
conveying substrate specificity and defining the cleavage profile. Thus identification of
amino acids in the I-TevI ND that result in relaxed specificity is a twofold success; in
addition to generating a relaxed specificity mutant, it provides indirect evidence of the
amino acids that convey specificity in the wild-type ND. My goal in this thesis has been
to determine if the I-TevI ND is responsible for controlling the cleavage motif cleavage
profile. I did this by testing the null hypothesis that mutagenesis of the I-TevI ND would
not alter the cleavage profile.
4.1 Directed Evolution of I-TevI Nuclease Domains
My  first  and  second  research  objectives  were  the  creation  of  a  library  of
mutagenised I-TevI ND from which I would try to identify I-TevI ND mutants that could
cleave substrates that the wild-type could not. In the preceding chapters, I described how
mutagenic PCR was used to generate a library of I-TevI ND mutants, from which NDs
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with altered specificities were selected over multiple rounds of directed evolution. Six
populations of mutant I-TevI NDs survived 4 rounds of selection on substrates AAG,
CCC, GAA, GCC, GGA, and TGG (population A-F, respectively). It was interesting that
in these 6 populations, all 12 individual mutants identified possessed either a T95S or a
Q158R  mutation.  This  was  the  first  indication  that  these  mutations  would  prove
important for altering the I-TevI ND cleavage profile. Another notable mutation was the
K26R mutation, which is immediately adjacent to the catalytically critical R27, and was
the only mutant  identified  in  combination  with both  Q158R and T95S,  indicating a
potentially significant impact on catalysis when combined with both of these mutations.
However,  the absence of K26R, C39R, or I86V mutations in isolation indicates that
these mutations may be less important for catalysis. Ultimately, the small sample size of
isolated mutants (5 per population), and the potential for a founder effect in the PCR
mutagenesis cast doubt on these assertions, and a more detailed study of these mutations
was needed; regardless, my first two objectives were complete.
4.2 Individual Mutations: Potential Impacts on Catalysis and Structure
My  third  objective  was  to  identify  individual  I-TevI  ND  mutations  or
combinations thereof that would confer survival against substrates that the wild-type ND
could not cleave. My intention was to identify the ND mutations that had the strongest
impact on survival, and thus were most likely to be of direct catalytic relevance. The
exact mechanism by which the mutations I identified alter specificity is unknown, and
was not directly attended to in this thesis; however, most of the mutations described
above  are  oriented  towards  the  putative  active  site  of  the  I-TevI  ND  (Figure  4.1),
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presenting a possibility for them to have a direct role in catalysis. Furthermore, some of
these mutations occur adjacent to residues with an established catalytic role.
4.2.1 Individual Mutations: K26R is Adjacent to Catalytically Critical R27
An R27A mutation in the I-TevI ND abolishes the second, top-strand, nicking
reaction  and  thus  R27  likely  has  a  direct  role  in  cleavage  of  the  top-strand
phosphodiester  bond.  Although  the  precise  mechanism of  I-TevI  is  not  known,  the
mechanism of other GIY-YIG NDs have been elucidated in greater detail. Hpy188I is a
RE from Helicobacter  pylori,  and contains a  GIY-YIG ND. Crystallographic studies
have  solved  the  structure  of  this  enzyme  with  its  substrate  bound,  in  which  R84
(analogous to R27 in I-TevI, Figure 3.5) is observed in a crystal structure orienting the
water molecule that makes a nucleophilic attack on the phosphodiester bond131. UvrC, a
component of the DNA damage repair pathway also contains a GIY-YIG ND, in which
R39 (analogous to R27 in I-TevI, Figure 3.5) appears to be involved in charge balancing
of the pentavalent phosphate intermediate that forms following nucleophilic attack by
water132.  Thus  K26R  may  simply  assist  R27  by  positioning  the  scissile  phosphate
accordingly, or it may stabilise the pentavalent phosphate intermediate that accompanies
phosphodiester bond cleavage as in the mechanism of the HE I-PpoI133, Eco29kI134, or
UvrC132.  One  intriguing  possibility  is  that  K26R is  acting  as  a  redundant  catalytic
residue, that steps in to catalyse cleavage of substrates for which the orientation of R27
is  sub-optimal  due  to  perturbations  of  DNA  backbone  structure  that  accompany
alterations of DNA sequence (in this case, the cleavage motif). Such a possibility could
be tested by generating a K26R R27A mutant, and testing for in vitro cleavage or in vivo
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H40
C39
K26
T95
I86
Figure 4.1. Mutations K26R, C39R, and T95S affect the I-TevI ND active site. 
Key catalytic residues H40 and R27 are oriented towards the active site groove of 
the I-TevI ND. K26, C39, and T95 are also oriented towards this groove, or could 
adopt a conformation to do so.
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survival as described in this thesis.
4.2.2 Individual Mutations: C39R is Adjacent to Catalytically Important H40
H40 has been identified as being catalytically important: H40Y is structurally
stable,  as evidenced by substrate bending studies, but is less able to effect catalysis.
Histidine residues typically contribute to catalysis by acting as a general base, stabilising
anionic intermediates via charge balancing or H-bonding, or by chelating metal atoms.
In the proposed mechanism of the GIY-YIG ND in Eco29kI, a histidine residue (which
does  not  coincide  with  H40  in  sequence  alignments  with  I-TevI)  is  responsible  for
deprotonating one of the conserved tyrosine residues of the GIY-YIG sequence, which
in turn deprotonates a water molecule such that it can nucleophilically attack the scissile
phosphate  to  effect  phosphodiester  bond cleavage134.  In  the  proposed mechanism of
Hpy188I, a histidine residue aids in coordinating the divalent metal ion responsible for
orienting the phosphodiester group such that nucleophilic attack by water ejects the 3'-
hydroxyl  group  of  the  downstream  nucleotide131.  Each  of  these  roles  could  be
modulated,  enhanced,  or  abolished by a  nearby guanidinium group,  as  in  the C39R
mutation.
It  is  worth  noting  that  cysteine  can  act  in  a  similar  fashion  to  the  histidine
residues in the examples above; however, given that this residue is not conserved across
GIY-YIG domains, and no C39A or similar mutations exist, it is currently difficult to
speculate about what catalytic role – if any – this residue could have. There also exists
the possibility that C39R has no direct catalytic impact at all. Consider that, as can be
seen in Figure 3.4, the C39R mutation has only a weak ability to confer survival. This
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weak influence  on  survival  is  in  contrast  to  the  strong influence  on survival  that  a
substitution directly involved in catalysis would be expected to have (e.g. catalytically
dead  R27A NDs  confers  no  selective  advantage  over  empty  backbone  vector,  as
evidenced by the <0.1% survival observed for both). These observations may point to
another possible explanation. C39 is notable for being present as a cystine in the I-TevI
R27A ND crystal structure (PDB ID: 1LN0)135, forming a disulfide bond to C39 of an
adjacent  I-TevI  ND.  Although  C39R  has  a  relatively  small  impact  on  changing
specificity,  it  may  reduce  the  sensitivity  of  the  ND  to  oxidative  stress  or  post-
translational modification, thus its role may be connected to in vivo stability moreso than
catalysis. It may be illuminating to measure or follow the expression of the MegaTev
chimaera with or without the C39R mutation using S35 pulse-chase to determine levels
of expression in the cell and turnover.
4.2.3 T95S: Implications for the I-TevI Nuclease Domain C-Terminal Region
T95S contributed significantly to survival against a number of poor substrates
with NNN substitutions (GAA, TGG, GCC, GGA, and CCC) but not against any of the
poor substrates with position 1 substitutions (C1A, C1G, or C1T). This could indicate
the role of this amino acid in I-TevI. T95 is located at the border of the ND and the
linker region, a region of poorly defined structure and function, however its impact on
NNN triplet  recognition suggests  that  this  region is  important  for defining how this
triplet is recognised. Because the triplets seem to be read – in part – through indirect
readout (i.e. through the response of the DNA to structural perturbations rather than by
specific H-bonding patterns of the major-groove surface) the C-terminal region of the
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ND in which T95S is found may be responsible for positioning the substrate for readout,
or straining the substrate  DNA to bring the catalytic  residues and substrate  into the
proper orientation (activated state) for catalysis. Such a difference might be borne out by
a thermodynamic study of the cleavage of substrates with varying NNN triplets by the I-
TevI wild-type and T3 ND to explore differences in ground-state substrate binding and
transition-state  binding between these two NDs,  and between cleavage resistant  and
cleavage facile substrates.
4.2.4 Significance of Similarities of Mutations to I-BmoI Sequence
Some  of  the  amino  acid  substitutions  identified  by  the  selections  described
herein  are  already  present  in  another  GIY-YIG  HE,  I-BmoI,  which  has  the  native
cleavage motif 5' – GCCCG – 3'. Thus a set of mutations were installed in I-TevI to
emulate the sequence of I-BmoI at these positions, namely K26S, C39R, and T95S, to
see if such substitutions led to marked improvement of cleavage of substrates similar to
the I-BmoI cleavage motif, namely C1G (5' – GAACG – 3') or CCC (5' – CCCCG – 3').
Disappointingly, K26S and C39R did not impart any significant advantage, either alone
or with other mutations, against substrates similar to the I-BmoI native cleavage motif.
However,  T95S was  singularly responsible  for  improved  survival  against  CCC,  and
another  K26 substitution,  K26R,  when combined  with  Q158R and  T95S,  conferred
survival against all position 1 substitutions, including C1G.
4.2.5 The Curious Case of Q158R 
One  of  the  mutations  identified  from  selections  was  particularly  surprising,
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namely  Q158R.  This  mutation  was  not  identified  in  any  of  the  regions  that  were
intentionally mutagenised, and likely arose spontaneously during PCR amplification of
the linker region during library construction. Furthermore, Q158 is within a ZF DBD
that  has  not  been  thus  far  linked  to  the  specificity  or  DNA-binding  affinity  of  the
enzyme136,  but  rather  to  distance  determination.  The  significant  increase  in  survival
conferred  by  Q158R  against  both  cleavage  resistant  NNN  triplets  and  position  1
cleavage motif  substitutions  cannot  easily be explained by altered  cleavage distance
determination,  especially  in  light  of  the  cleavage  motif  sequencing  results,  which
indicate that in fact the cleavage site has not changed. 
One possible reason for the impact of the Q158R mutation on survival may be
that  it  is  acting  as  a  suppressing  mutation  of  sorts,  and  counteracting  disturbances
created in the linker due to the fusion of residues 1-169 of I-TevI to I-OnuI E1 E22Q.
This mechanism of expanding the cleavage profile of I-TevI could be investigated by
including Q158R in chimaeric MegaTevs that have more of the native linker region
between the ND and I-OnuI E1 E22Q. If a MegaTev with a longer linker does not have a
broader cleavage specificity after inclusion of Q158R, then it would be unlikely that this
substitution suppresses the effect of fusions made only 11 aa downstream to the same
extent as fusions made as many as 37 aa downstream (as would be the case for fusions
with residues 1-201 of I-TevI)6. A more likely cause for this result in this case would be
that  the  substitution  effects  its  change upstream instead,  perhaps  by influencing the
orientation of the linker, and through mechanical coupling, the orientation of the ND.
4.2.6 The Triple Mutant: K26R T95S Q158R (T3)
67
The  most  promising  individual  mutations  identified  in  survival  assays  were
K26R, T95S, and Q158R. Unsurprisingly, when these mutations were combined into a
single  triple  mutant,  the  result  was  an  I-TevI  ND  and  linker  with  a  significantly
expanded  survivability  in  survival  assays.  The  creation  of  a  triple  ND mutant  with
expanded survivability is not consistent with the null hypothesis that the I-TevI ND is
not  responsible  for the cleavage motif  cleavage profile.  However,  since the survival
assays  do  not  measure  cleavage  per  se, it  was  not  known  whether  or  not  these
substitutions were the result of a change in the catalytic activity and cleavage profile of
the ND. Thus these results were not necessarily  inconsistent  with the null hypothesis
either, and direct measurement of cleavage using in vitro assays was indicated. 
4.3 Information Gleaned From in vitro Assays 
My  fourth  research  objective  was  to  overexpress,  purify  and  kinetically
characterise  an  I-TevI  ND mutant  to  determine  its  cleavage  profile.  If  the  cleavage
profile has clearly changed in a manner consistent with the ND mutations assayed  in
vivo, then indeed the ND is at least partly responsible for defining the cleavage motif
cleavage  profile.  As  alluded  to  in  the  previous  section,  in  vivo data  obtained  from
survival  assays  cannot  be  directly  correlated  with  activity  because  of  numerous
convoluting variables in a biological system. Indeed, tight regulation of HEs is required
to  prevent  detrimental  effects  to  the  host  organism137,138,  which  are  not  necessarily
replicated in the bacterial 2-plasmid system. Thus survival may be conveyed through
reduced toxicity (e.g. reduced affinity/activity for some as-yet unknown site in a critical
component of the E. coli genome), increased in vivo stability leading to higher steady-
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state  enzyme  concentrations,  or  even  through  unanticipated  downregulation  of  the
topoisomerase  inhibitor  used  as  selective  pressure  in  these  assays,  similar  to  the
autoregulation of wild-type I-TevI, in which I-TevI binds and obscures a regulatory site,
but cannot cut it because of an absent cleavage motif137. Even if these results are due to a
catalytic effect, the data presented in sections 3.1 and 3.2 does not discriminate between
increased  activity  against  all  substrates  (since  there  is  an  upper  bound  of  ~100%
survival), or altered specificity through increased promiscuity. Furthermore, the in vivo
data provides only a coarse estimate of activity since the standard error for such an
experiment can be quite large. Thus,  in vitro assays are indispensable for distilling the
enzymatic  consequences  from a  whole-cell  system;  this  kind  of  experiment  has  the
sensitivity to discriminate between increased activity against all substrates. 
In general, it can be seen that the T3 ND cleaves the cleavage-resistant substrates
more efficiently than the wild-type ND, as measured by the first order rate constant that
describes the decay of each substrate over time. For some substrates assayed (e.g. GCA,
GTG, and GCT) there was a large disparity between the in vitro cleavage rates between
wild-type and T3 NDs, but relatively a relatively small enhancement of in vivo survival
rate by the T3 ND. Conversely, assay of some substrates (e.g. CCC, and AAG) revealed
a comparatively small disparity between in vitro cleavage rates, despite a large increase
in survival. Although this initially seemed to point to a conflict between the two data
sets,  further  examination  revealed  that  the  data  is  quite  consistent  with  a  threshold
effect:  survival  in  vivo corresponded  to  a  relative  kapp value  greater  than  or
approximately equal to 0.5. 
While this correlation is somewhat crude and exceptions exist, it could be still be
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used as a rough measure of the extent of convoluting variables affecting in vivo data: if
the in vitro data suggest that there clearly should or should not be survival for a chosen
enzyme-substrate  pairing,  then  conflicting  in  vivo data  would indicate  that  variables
other  than  cleavage  rate  may  need  to  be  considered.  That  being  said,  further
characterisation to ensure this threshold effect is observed with other substrates in vitro
and in vivo would be necessary to give confidence to such a metric. 
The NNN triplets presented in Figure 3.8 represent only half of all possible NNN
triplets. Thus one obvious step forward will be to determine the exact kinetic impact of
each of these mutations on cleavage of all 64 possible NNNs. Another consideration that
was  not  attended  to  in  this  thesis  is  the  impact  that  these  mutations  may have  on
cleavage of position 5 substitutions. Although the position 5 G of the I-TevI cleavage
motif,  like  the  position  1  C  has  been  previously  demonstrated  to  be  required  for
cleavage,  the  mutations  I've  described  above  may  provide  the  ability  to  relax  this
requirement. 
4.4 Future Directions
Although  the  results  of  the  work  described  in  this  thesis  are  inherently
informative,  they also form the foundation of  the  project  that  I  will  be undertaking
towards completion of my PhD thesis: a thermodynamic and kinetic investigation of the
underlying cause of the I-TevI cleavage profile. As mentioned in the introduction to this
thesis,  there  is  no  obvious  pattern  to  the  NNN triplets  that  I-TevI  will  cleave,  and
indirect  readout  through  the  biophysical  characteristics  of  the  triplets  is  likely
responsible  for  the  cryptic  cleavage  profile.  By identifying  I-TevI  ND mutants  that
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present  an  altered  cleavage profile,  I  can  begin  identifying correlations  between the
specific  thermodynamic and kinetic characteristics of the mutants,  and the ability to
cleave a particular NNN triplet. In the same spirit as Prof. Richard Feynman's famous
words, “If I can build it, then I understand it” my hope is that these correlations can be
used  to  reverse  engineer  I-TevI  NDs  with  practically  any  desired  cleavage  profile.
Below are briefly described some of the projects I will be pursuing in my PhD, which
are derived from the results in this thesis.
4.4.1 Additional Directed Evolution of I-TevI Nuclease Domains
Although there was extensive redundancy in the mutations identified from my
genetic selections, a more thorough exploration of the surviving I-TevI ND mutants may
identify additional mutations that expand the I-TevI ND cleavage profile, diminish the
number  of  cleavage  resistant  substrates,  and  complement  experiments  designed  to
elucidate the mechanism by which ND mutations expand the I-TevI cleavage profile.
In engineering an enzyme with a new substrate specificity, it can be useful to
first develop a more promiscuous enzyme capable of acting on both its original substrate
and the new substrate. This promiscuous enzyme can then be refined to act selectively
on the new substrate. I propose that the same approach could be applied to the I-TevI
ND. The T3 mutant has a more relaxed cleavage profile compared to wild-type, for the
set of substrates assayed thus far. An I-TevI ND mutant with an orthogonal cleavage
profile might be developed by further mutagensing the T3 mutant, and then conducting
rounds  of  selection  in  which  cleavage  of  a  chosen substrate  is  selected  against,  by
including the corresponding target site into the pEndo vector, which harbours the I-TevI
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ND mutant itself. Thus only mutants that cleave the target site in pTox, but not in pEndo
will  be  maintained  in  the  population.  Mutations  identified  by  such  a  bi-functional
selection could not only inform on those amino acids that facilitate cleavage of cleavage
resistant substrates, but also reveal those amino acids that must be maintained in order to
facilitate cleavage of the target site included on pEndo.
4.4.2 Kinetic Investigations of the I-TevI Nuclease Domain Cleavage Profile
I-TevI has a two step mechanism in which the bottom strand is nicked prior to
cleavage.  Studies  with I-BmoI  have  indicated that  the  rate  of  each  nicking reaction
varies  depending  on  the  chemical  environment  of  the  ND  active  site,  namely  the
divalent metal ion present139. I posit that the resistance of each NNN triplet to cleavage
is  mediated  by  perturbing  the  active  site  chemical  environment,  and  that  this  will
manifest as a reduction of the rate of one or both nicking reactions. Moreover, I propose
that the extent to which each nicking reaction is compromised may be correlated to the
nucleobases on the same strand as, and directly adjacent to, the scissile phosphate. This
information is hidden in measurements of overall cleavage (such as the barcode assay)
because overall cleavage would proceed at a rate defined only by the nicking reaction
that becomes the rate-limiting step. I further propose that the ND mutants that I have
identified  will  display  an  increase  in  the  rate  of  one  or  both  nicking  reactions.
Collectively, I expect that the substrates that a particular mutant cleaves better than wild-
type  will  be  those  substrates  that  compromise  the  same  nicking  reaction  that  the
mutation accelerates.  In other words: the cleavage-resistant substrates impose a rate-
limiting step that the mutations counterbalance,  such that on the whole,  the reaction
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proceeds efficiently.
4.4.3 Thermodynamic Investigations of the I-TevI Nuclease Domain Cleavage Profile
Even  in  the  absence  of  direct  observation,  there  is  a  great  deal  about  the
mechanism of an enzyme that can be elucidated by examining the thermodynamics of its
function. The extent to which a particular kinetic constant varies with temperature can
be used to determine thermodynamic constants for that reaction, such as the individual
contributions of enthalpy and entropy changes to transition state stabilisation and ground
state destabilisation140,141.  An enzyme that contorts  its substrate might be expected to
strongly reduce the entropy of bound substrate, as it is gripped tightly and forced into an
unfavourable conformation. Such contortions would have to be compensated for by a
similarly  strong  reduction  of  enthalpy,  typically  effected  using  extensive  hydrogen
bonding, close packing of hydrophobic surfaces, and geometrically optimal salt bridges.
As discussed in the introduction, indirect readout seemingly plays a part in the I-TevI
ND cleavage profile. Since indirect readout is in essence recognising the response of a
segment of DNA to strain, I propose that cleavage of the native I-TevI cleavage motif
will be accompanied by a large decrease in entropy. It stands to reason that indirect
readout  cannot  function properly if  the required  strain  cannot  be generated.  Thus,  I
propose that cleavage resistant substrates are as such because they are also resistant to
the  contortions  required  for  indirect  readout,  either  because  they are  too  stiff  to  be
contorted  to  a  significant  degree,  or  they  are  flexible  and  are  able  to  contort  their
structure without induction of significant strain. In either case, I expect that cleavage
resistance will  manifest  as a complete or partial  mitigation of the large reduction of
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entropy anticipated for binding of the native target. Consequently, I propose that the I-
TevI ND mutants that effect cleavage of cleavage resistant substrates will display an
enhanced reduction of entropy upon substrate binding regardless of the substrate being
cleaved.
4.5 Conclusions
Efforts  to  re-engineer  nucleases  have made significant  progress over the past
decade. However, these efforts have also proven challenging, and the goal of a fully
customiseable  nuclease  is  still  incomplete.  This  work  represents  the  first  time  the
cleavage specificity towards the I-TevI cleavage motif has been altered. Furthermore,
since the I-TevI ND and partial linker are portable to other DBDs, this result is a step
towards improving the versatility of a genome editing system in which a DBD and an I-
TevI ND mutant are combined on the basis of their specificity to effect genome editing
at  any chosen locus.  Additional  work will  be required to further  alter  and hone the
specificity of these mutants, using both positive selection as described above, and an
additional  negative  selection,  which  eliminates  ND mutants  that  cleave  a  particular
cleavage  motif  by  –  for  instance  –  placing  that  cleavage  motif  in  the  ND  mutant
expression plasmid. Perhaps more importantly,  the mechanism by which the mutants
identified by genetic selection change the I-TevI cleavage profile is poorly understood
and requires further study.
Engineering successes and newly opened avenues of research aside, the question
remains:  were the  results  of  this  thesis  consistent  with  the  null  hypothesis  or  no?  I
observed that the ND mutations K26R and T95S were able to expand survivability  in
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vivo,  especially  when  combined  with  Q158R.  Importantly,  Q158R was  not  able  to
confer survival against some NNNs such as TGG without the assistance of K26R, and
especially T95S. However, it could be argued that the inclusion of Q158R undermines
the premise of the experiment. Q158R is not a ND mutation, and its influence on the
cleavage motif cleavage profile convolutes the influence of the true ND mutations. Yet,
the correlation between  in vitro cleavage and  in vivo survival strongly suggests that
pronounced survival against a substrate was the result of substrate cleavage. The single
mutant  T95S  was  able  to  confer  pronounced  survival  against  an  expanded  set  of
substrates, which in light of the correlation between survival and cleavage, indicates
that it did indeed relax the cleavage motif cleavage profile, in direct conflict with the
null hypothesis.
 I  think  it  is  worth  noting,  however,  that  whatever  contribution  the  T95S
mutation had on relaxing the I-TevI cleavage profile, it was greatly augmented by the
addition of Q158R. Further, T95S is at the extreme limit of the canonically defined ND
of I-TevI, and those mutations that were clearly within the ND proved far less capable of
conferring  expanded  survivability  in  vivo.  Thus  I  propose  a  new  hypothesis:  The
cleavage motif cleavage profile is defined in part by residues within the I-TevI ND, and
in part by residues of the linker region, and that these residues work cooperatively. 
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Appendix 1: Bacterial strains, plasmids and primers used for the development of
this thesis, and raw data underlying the results.
Below are  found tables  listing  the  all  of  the  bacterial  strains,  plasmids,  and
primers used to develop this thesis (Table S.1, S.2, and S.3, respectively). Also included
are tables quantifying the results of the numerous survival assays completed to generate
figure 3.4 (Table S.4). Finally, a table of data summarising the  kapp-values (Table S.5)
and the plots with fitting data used to derive them (Figure S.1)
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Supplem
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ids use d in this study
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Name Sequence (5'-3')
DE410 GGAAGAAGTGGCTGATCTCAGC
DE411 CAGACCGCTTCTGCGTTCTG
DE840
DE1045
DE1424 CGTTTGGTGATACATGTTCTACG
DE1912
DE2183
DE2184
DE2222 CCCAAACAGGTCGCTGAAATGC
DE2223 TGTCACGCTCGTCGTTTGGTATGGC
DE2224 ATGACGACCGTAGTGATGAATCTCTCC
DE2225 TCATGGTTATGGCAGCACTGC
DE2226 AAAAAAATCGAGATAACCGTTGGC
DE2227 CCGCGCCACATAGCAGAACTTTAAAAGTGC
DE2228 ATTGTCCATATTGCATCAGACATTGC
DE2229 ACTTCACCAGCGTTTCTGG
DE2230 AAATTAATAGGTTGTATTGATGTTGGACGAGTCG
DE2231 AAATTGCAGTTTCATTTGATGCTCG
DE2296 TGAGACACAACGTGGCTTTGTTGAATAAATCG
DE2297 TCCATGTTGGAATTTAATCGCGGCCTCG
Supplemental Table S3: Oligonucleotides used in this study
Notes1
Forward primer to generate all cycle-seq products for 
target sites cloned into pTox
Reverse primer to generate all cycle-seq products for 
target sites cloned into pTox
GCCGCCATGGGTAAAAGCGGAATTTATCAGATT
Forward primer for I-TevI  cloning, NcoI site 
underlined
CGCGGATCCATTTCTGCATTTACTACAAG
Reverse primer for TevN169 cloning, BamHI site 
underlined
Reverse primer for I-TevI linker cloning.
CGTAGAACATGTATCACCAAACG
Reverse primer for mutagenesis of the I-TevI nuclease 
domain, PciI site is underlined
GGAAGTGCTAAAGATTTTGAATCGAGATGGAAGAGGCATTTT
AAAG
Forward primer for installation of K26S into top 
strand.
CTTTAAAATGCCTCTTCCATCTCGATTCAAAATCTTTAGCACT
CCC
Reverse primer for installation of K26S into bottom 
strand.
Forward primer for generating the 2200 bp barcode 
assay substrate from pTox or pKox templates.
Reverse primer for generating the 2200 bp barcode 
assay substrate from pTox templates.
Forward primer for generating the 1900 bp barcode 
assay substrate from pTox or pKox templates.
Reverse primer for generating the 1900 bp barcode 
assay substrate from pTox templates.
Forward primer for generating the 1600 bp barcode 
assay substrate from pTox or pKox templates.
Reverse primer for generating the 1600 bp barcode 
assay substrate from pTox or pKox templates.
Forward primer for generating the 1300 bp barcode 
assay substrate from pTox or pKox templates.
Forward primer for generating the 1300 bp barcode 
assay substrate from pTox or pKox templates.
Reverse primer for generating the 2200 bp native I-TevI 
target barcode assay substrate from pKox templates.
Reverse primer for generating the 1900 bp native I-TevI 
target barcode assay substrate from pKox templates.
Reverse primer for generating the 1900 bp non-native I-
TevI target barcode assay substrate from pKox 
templates.
Reverse primer for generating the 2200 bp non-native I-
TevI target barcode assay substrate from pKox 
templates.
1 underlined nucleotides refer to restriction enzyme sites
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C
C
A
0.00±0.00
0.00±0.00
0.00±0.00
0.00±0.00
0.00±0.00
0.00±0.00
0.00±0.00
0.00±0.00
4.97±6.26
C
A
G
0.00±0.00
0.00±0.00
0.00±0.00
0.00±0.00
0.00±0.00
0.00±0.00
0.00±0.00
0.00±0.00
2.33±0.55
C
C
C
4.13±0.68
12.67±20.21
0.00±0.00
0.00±0.00
0.00±0.00
0.00±0.00
0.00±0.00
0.00±0.00
64.00±53.23
A
A
G
0.00±0.00
0.00±0.00
26.33±9.07
14.27±7.75
4.60±2.56
14.27±13.13
0.00±0.00
0.00±0.00
54.00±24.25
G
A
G
0.00±0.00
0.00±0.00
0.00±0.00
0.00±0.00
0.00±0.00
0.00±0.00
0.00±0.00
0.00±0.00
0.00±0.00
A
C
G
0.00±0.00
0.00±0.00
0.00±0.00
0.00±0.00
0.00±0.00
0.00±0.00
0.00±0.00
0.00±0.00
24.67±21.94
C
1A
0.00±0.00
0.00±0.00
0.00±0.00
0.00±0.00
0.00±0.00
0.00±0.00
0.00±0.00
0.00±0.00
3.07±2.16
C
1G
0.00±0.00
0.00±0.00
0.00±0.00
0.00±0.00
0.00±0.00
0.00±0.00
0.00±0.00
0.00±0.00
4.93±2.78
C
1T
0.00±0.00
0.80±0.44
0.00±0.00
0.00±0.00
0.00±0.00
0.00±0.00
0.00±0.00
0.00±0.00
107.33±51.52
T
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Substrate wild-type T3 Substrate wild-type T3
AAA 0.73 + 0.08 0.41 + 0.05 AAC 1.07 + 0.18 0.29 + 0.04
AAC 1.00 + 0.11 0.33 + 0.05 CCG 0.02 + 0.01 0.07 + 0.01
AAG 0.38 + 0.04 0.17 + 0.02 GCG 0.05 + 0.01 0.10 + 0.01
AAT 1.07 + 0.14 0.32 + 0.04 TCG 0.21 + 0.02 0.23 + 0.03
AAC 0.74 + 0.07 0.85 + 0.09 AAC 0.63 + 0.06 0.15 + 0.04
CCC 0.27 + 0.02 0.41 + 0.03 CGG 0.032 + 0.004 0.02 + 0.02
GCC 0.26 + 0.03 0.69 + 0.06 GGG 0.12 + 0.01 0.11 + 0.03
TCC 0.58 + 0.06 0.72 + 0.07 TGG 0.18 + 0.01 0.13 + 0.02
AAC 0.74 + 0.06 0.63 + 0.07 AAC 0.51 + 0.05 0.40 + 0.05
CAG 0.14 + 0.01 0.11 + 0.01 CTG 0.08 + 0.01 0.25 + 0.04
GAG 0.16 + 0.01 0.18 + 0.01 GTG 0.15 + 0.01 0.17 + 0.02
TAG 0.29 + 0.01 0.37 + 0.03 TTG 0.32 + 0.02 0.26 + 0.03
AAC 1.00 + 0.07 0.85 + 0.09 AAC 0.63 + 0.04 0.11 + 0.01
ACG 0.27 + 0.02 0.41 + 0.03 CCT 0.28 + 0.01 0.083 + 0.005
AGG 0.38 + 0.03 0.69 + 0.06 GCT 0.11 + 0.00 0.078 + 0.005
ATG 0.48 + 0.07 0.72 + 0.07 TCT 0.21 + 0.01 0.10 + 0.01
AAC 0.90 + 0.09 0.53 + 0.06 C1A 0.15 + 0.02 0.05 + 0.01
CCA 0.12 + 0.02 0.08 + 0.00 C1C 0.78 + 0.05 0.16 + 0.02
GCA 0.26 + 0.03 0.27 + 0.02 C1G 0.10 + 0.01 0.08 + 0.01
TCA 0.60 + 0.06 0.45 + 0.05 C1T 0.10 + 0.01 0.10 + 0.01
AAC 0.57 + 0.04 0.35 + 0.06 2200 0.75 + 0.07
CGA 0.041 + 0.002 0.05 + 0.01 1900 0.77 + 0.08
GGA 0.072 + 0.003 0.22 + 0.02 1600 0.67 + 0.08
TGA 0.20 + 0.01 0.32 + 0.04 1320 0.63 + 0.06
Table S.5. Apparent First-Order Rate Constants for 
Substrate Decay by Chimaeric MegaTevs with wild-type or T3 NDs 
kapp kapp
n.d.*
n.d.*
n.d.*
n.d.*
*Not determined
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Figure S.1. Barcode assay kinetic data. MegaTevs with a wild-type ND (WT 
[A, C, E, G, I, K, M, O, Q, S, U, W, X]) and MegaTevs with a triple mutant K26R 
T95S Q158R (T3 [B, D, F, H, J, L, N, P, R, T, V]) were assayed against four 
substrates of varying lengths (2200 [yellow ▲], 1900 [blue ▲], 1600 [green ▲], 
and 1320 bp [red ▲]). Substrates harboured I-TevI cleavage motifs, one of which 
was the native cleavage motif (5' – CAACG – 3'), and the others were comprised 
of NNN triplet substitutions (5' – CNNNG – 3' [A-T]), position 1 substitutions (5' 
– NAACG – 3' [U, V]), or control substrates. The controls involved  either all 
native cleavage motifs, one of each of four lengths (W), or a single native 
cleavage motif (1C5G [X]) among cleavage resistant motifs (5' – AAACA – 3', 
1A5A [X]). All assays were conducted at 5°C, with 250 nM enzyme, and 5 nm of 
each substrate. The equation of fit is explained in detail in the text (see eqn. 2.2). 
Note that the equation given below is superficially different; using the identities y 
= fS, and x = t, the equations below become eqn 2.2.
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